Welcome to Current Psychiatry, a leading source of information, online and in print, for practitioners of psychiatry and its related subspecialties, including addiction psychiatry, child and adolescent psychiatry, and geriatric psychiatry. This Web site contains evidence-based reviews of the prevention, diagnosis, and treatment of mental illness and psychological disorders; case reports; updates on psychopharmacology; news about the specialty of psychiatry; pearls for practice; and other topics of interest and use to this audience.

Theme
medstat_cp
Top Sections
Evidence-Based Reviews
Cases That Test Your Skills
cp

Dear Drupal User: You're seeing this because you're logged in to Drupal, and not redirected to MDedge.com/psychiatry. 

Main menu
CP Main Menu
Explore menu
CP Explore Menu
Proclivity ID
18803001
Unpublish
Negative Keywords
Bipolar depression
Depression
adolescent depression
adolescent major depressive disorder
adolescent schizophrenia
adolescent with major depressive disorder
animals
autism
baby
brexpiprazole
child
child bipolar
child depression
child schizophrenia
children with bipolar disorder
children with depression
children with major depressive disorder
compulsive behaviors
cure
elderly bipolar
elderly depression
elderly major depressive disorder
elderly schizophrenia
elderly with dementia
first break
first episode
gambling
gaming
geriatric depression
geriatric major depressive disorder
geriatric schizophrenia
infant
kid
major depressive disorder
major depressive disorder in adolescents
major depressive disorder in children
parenting
pediatric
pediatric bipolar
pediatric depression
pediatric major depressive disorder
pediatric schizophrenia
pregnancy
pregnant
rexulti
skin care
teen
wine
Negative Keywords Excluded Elements
header[@id='header']
section[contains(@class, 'nav-hidden')]
footer[@id='footer']
div[contains(@class, 'pane-pub-article-current-psychiatry')]
div[contains(@class, 'pane-pub-home-current-psychiatry')]
div[contains(@class, 'pane-pub-topic-current-psychiatry')]
div[contains(@class, 'panel-panel-inner')]
div[contains(@class, 'pane-node-field-article-topics')]
section[contains(@class, 'footer-nav-section-wrapper')]
Altmetric
DSM Affiliated
Display in offset block
QuickLearn Excluded Topics/Sections
Best Practices
CME
CME Supplements
Education Center
Medical Education Library
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Clinical
Slot System
Top 25
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
Publication LayerRX Default ID
798,799
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC

10 Recent paradigm shifts in the neurobiology and treatment of depression

Article Type
Changed
Thu, 03/28/2019 - 15:32
Display Headline
10 Recent paradigm shifts in the neurobiology and treatment of depression

Nowhere is that change in landscape more apparent than in major depression, the No. 1 disabling condition in all of medicine, according to the World Health Organization. The past decade has gen­erated at least 10 paradigm shifts in the neurobiology and pharmacotherapeutics of depression.


Clinging to simplistic tradition

Most contemporary clinicians con­tinue to practice the traditional model of depression, which is based on the assumption that depression is caused by a deficiency of monoamines: sero­tonin (5-HT) and norepinephrine (NE). The entire antidepressant armamentar­ium approved for use by the FDA was designed according to the amine defi­ciency hypothesis. Depressed patients uniformly receive reuptake inhibitors of 5-HT and NE, but few achieve full remission, as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed.1

As scientific paradigm shifts infil­trate clinical practice, however, the tired notion of “chemical imbalance” will yield to more complex and evidence-based models.

Usually, it would be remarkable to witness a single paradigm shift in the understanding of a brain disor­der. Imagine the disruptive impact of multiple scientific shifts within the past decade! Consider the follow­ing departures from the old dogma about the simplistic old explanation of depression.


1. From neurotransmitters to neuroplasticity

For half a century, our field tenaciously held to the monoamine theory, which posits that depression is caused by a deficiency of 5-HT or NE, or both. All antidepressants in use today were developed to increase brain mono­amines by inhibiting their reuptake at the synaptic cleft. Now, research points to other causes:
   • impaired neuroplasticity
   • a decrement of neurogenesis
   • synaptic deficits
   • decreased neurotrophins (such as brain-derived neurotrophic factor)
   • dendritic pathology.2,3


2. From ‘chemical imbalance’ to neuroinflammation

The simplistic notion that depression is a chemical imbalance, so to speak, in the brain is giving way to rapidly emerging evidence that depression is associated with neuroinflammation.4

Pro-inflammatory cytokines are elevated in the plasma of depressed patients, and subside when the acute episode is treated. Current antidepres­sants actually have anti-inflammatory effects that have gone unrecognized.5 A meta-analysis of the use of anti-inflammatory agents (such as nonste­roidal anti-inflammatory drugs and aspirin) in depression shows promising efficacy.6 Some inflammatory markers, such as C-reactive protein, already have been reported to predict response to some antidepressants, but not to others.7


3. From 5-HT and NE pathways to glutamate NMDA receptors

Recent landmark studies8 have, taken together, demonstrated that a single IV dose of the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine (a psychotogenic drug of abuse FDA-approved only as an anesthetic) can produce clinical improvement of severe depression and even full remission for several days. Such studies demonstrate that the old dogma of 5-HT and NE deficiency might not be a valid over­arching hypothesis of the depression syndrome.

Long-term maintenance studies of ketamine to document its safety and continued efficacy need to be con­ducted. The mechanism of action of ket­amine is believed to be a rapid trigger for enhancing neuroplasticity.


4. From oral to parenteral administration

Several studies have been published showing the efficacy of IV or intranasal administration of new agents for depres­sion. Ketamine studies, for example, were conducted using an IV infusion of a 150-mg dose over 1 hour. Other IV studies used the anticholinergic scopolamine.9

Intranasal ketamine also has been shown to be clinically efficacious.10 Inhalable nitrous oxide (laughing gas, an NMDA antagonist) recently was reported to improve depression as well.11

It is possible that parenteral admin­istration of antidepressant agents may exert a different neurobiological effect and provide a more rapid response than oral medication.


5. From delayed efficacy (weeks) to immediate onset (1 or 2 hours)

The widely entrenched notion that depression takes several weeks to improve with an antidepressant has collapsed with emerging evidence that symptoms of the disorder (even sui­cidal ideation) can be reversed within 1 or 2 hours.12 IV ketamine isn’t the only example; IV scopolamine,9 inhalable nitrous oxide,11 and overnight sleep deprivation13 also exert a rapid thera­peutic effect. This is a major rethinking of how quickly the curtain of severe depression can be lifted, and is great news for patients and their family.


6. From psychological symptoms to cortical or subcortical changes

Depression traditionally has been recog­nized as a clinical syndrome of sadness, self-deprecation, cognitive dulling, and vegetative symptoms. In recent stud­ies, however, researchers report that low hippocampus volume14 in healthy young girls predicts future depression. Patients with unremitting depression have been reported to have an abnor­mally shaped hippocampus.15

In addition, gray-matter volume in the subgenual anterior cingulate (Brodmann area 24) is hypoplastic in depressed persons,16 making that area a target for deep-brain stimulation (DBS). Brain morphological changes such as a hypoplastic hippocampus might become useful biomarkers for identify­ing persons at risk of severe depression, and might become a useful adjunc­tive biomarker for making a clinical diagnosis.

 

 


7. From healing the mind to repairing the brain

It is well-established that depression is associated with loss of dendritic spines and arborizations, loss of syn­apses, and diminishment of glial cells, especially in the hippocampus17 and anterior cingulate.18 Treating depression, whether pharmaceutical or somatic, involves reversing these changes by increasing neurotrophic factors, enhancing neurogenesis and gliogenesis, and restoring synaptic and dendritic health and cell survival in the hippocampus and frontal cor­tex.19,20 Treating depression involves brain repair, which is reflected, ulti­mately, in healing the mind.


8. From pharmacotherapy to neuromodulation

Although drugs remain the predomi­nant treatment modality for depression, there is palpable escalation in the use of neuromodulation methods.

The oldest of these neuromodulatory techniques is electroconvulsive ther­apy, an excellent treatment for severe depression (and one that enhances hip­pocampal neurogenesis). In addition, several novel neuromodulation meth­ods have been approved (transcranial magnetic stimulation and vagus nerve stimulation) or are in development (transcranial direct-current stimula­tion, cranial electrotherapy stimulation, and DBS).21 These somatic approaches to treating the brain directly to allevi­ate depression target regions involved in depression and reduce the needless risks associated with exposing other organ systems to a drug.


9. From monotherapy to combination therapy

The use of combination therapy for depression has escalated with FDA approval of adjunctive use of atypical antipsychotics in unipolar and bipolar depression. In addition, the landmark STAR*D study1 demonstrated the value of augmentation therapy with a second antidepressant when 1 agent fails. Other controlled studies have shown that combining 2 antidepressants is superior to administering 1.22

Just as other serious medical dis­orders—such as cancer and hyper­tension—are treated with 2 or 3 medications, severe depression might require a similar strategy. The field gradually is adopting that approach.


10. From cortical folds to wrinkles on the face
Last, a new (and unexpected) paradigm shift recently emerged, which is genu­inely intriguing—even baffling. Using placebo-controlled designs, several researchers have reported significant, persistent improvement of depressive symptoms after injection of onabotu­linumtoxinA in the corrugator muscles of the glabellar region of the face, where the omega sign often appears in a depressed person.23,24

The longest of the studies25 was 6 months; investigators reported that improvement continued even after the effect of the botulinum toxin on the omega sign wore off. The proposed mechanism of action is the facial feed­back hypothesis, which suggests that, biologically, facial expression has an impact on one’s emotional state.


Big payoffs coming from research in neuroscience

These 10 paradigm shifts in a single psychiatric syndrome are emblematic of exciting clinical and research advances in our field. Like all syndromes, depression is associated with multiple genetic and environmental causes; it isn’t surprising that myriad treatment approaches are emerging.

The days of clinging to monolithic, serendipity-generated models surely are over. Evidence-based psychiatric brain research is shattering aging dog­mas that have, for decades, stifled inno­vation in psychiatric therapeutics that is now moving in novel directions.

Take note, however, that the only par­adigm shift that matters to depressed patients is the one that transcends mere control of their symptoms and restores their wellness, functional capacity, and quality of life. With the explosive momentum of neuroscience discovery, psychiatry is, at last, poised to deliver—in splendid, even seismic, fashion.

References


1. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Eng J Med. 2006;354(12):1243-1252.
2. Serafini G, Hayley S, Pompili M, et al. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets [published online November 30, 2014]? CNS Neurol Disord Drug Targets. doi: 10.2174/1871527313666141130223723.
3. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
4. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105-114.
5. Sacre S, Medghalichi M, Gregory B, et al. Fluoxetine and citalopram exhibit potent anti-inflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010;62(3):683-693.
6. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
7. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortiptyline. Am J Psychiatry. 2014;171(14):1278-1286.
8. Abdallah CG, Sanacora G, Duman RS, et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics [published online October 17, 2014]. Annual Rev Med. doi: 10.1146/annurev-med-053013-062946.
9. Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35(12):2479-2488.
10. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014; 76(12):970-976.
11. Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial [published December 14, 2014]. Biol Psychiatry. doi: http://dx.doi.org/10.1016/j.biopsych.2014.11.016.
12. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
13. Bunney BG, Bunney WE. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol Psychiatry. 2013;73(12):1164-1171.
14. Chen MC, Hamilton JP, Gotlib IH. Decreased hippocampal volume in healthy girls at risk for depression. Arch Gen Psychiatry. 2010;67(3):270-276.
15. Tae WS, Kim SS, Lee KU, et al. Hippocampal shape deformation in female patients with unremitting major depressive disorder. AJNR Am J Neuroradiol. 2011;32(4):671-676.
16. Hamani C, Mayberg H, Synder B, et al. Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. J Neurosurg. 2009;111(6):1209-1215.
17. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518.
18. Redlich R, Almeoda JJ, Grotegerd D, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression. A voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 2014;71(11):1222-1230.
19. Mendez-David I, Hen R, Gardier AM, et al. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr. 2013;71(3):143-149.
20. Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2(3):49-57.
21. Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology. 2012;37(1):102-116.
22. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
23. Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574-581.
24. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014;52:1-6.
25. Magid M, Reichenberg JS, Poth PE, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837-844.

Article PDF
Author and Disclosure Information

Henry A. Nasrallah, MD
Editor-in-Chief

Issue
Current Psychiatry - 14(2)
Publications
Topics
Page Number
10-13
Legacy Keywords
neurobiology, depression, treatment of depression, psychopathology, changes in psychiatry, pharmacology, neuromodulation, monotherapy, combination therapy, neuroinflammation, neurotrasmitters, neuroplasticity
Sections
Author and Disclosure Information

Henry A. Nasrallah, MD
Editor-in-Chief

Author and Disclosure Information

Henry A. Nasrallah, MD
Editor-in-Chief

Article PDF
Article PDF

Nowhere is that change in landscape more apparent than in major depression, the No. 1 disabling condition in all of medicine, according to the World Health Organization. The past decade has gen­erated at least 10 paradigm shifts in the neurobiology and pharmacotherapeutics of depression.


Clinging to simplistic tradition

Most contemporary clinicians con­tinue to practice the traditional model of depression, which is based on the assumption that depression is caused by a deficiency of monoamines: sero­tonin (5-HT) and norepinephrine (NE). The entire antidepressant armamentar­ium approved for use by the FDA was designed according to the amine defi­ciency hypothesis. Depressed patients uniformly receive reuptake inhibitors of 5-HT and NE, but few achieve full remission, as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed.1

As scientific paradigm shifts infil­trate clinical practice, however, the tired notion of “chemical imbalance” will yield to more complex and evidence-based models.

Usually, it would be remarkable to witness a single paradigm shift in the understanding of a brain disor­der. Imagine the disruptive impact of multiple scientific shifts within the past decade! Consider the follow­ing departures from the old dogma about the simplistic old explanation of depression.


1. From neurotransmitters to neuroplasticity

For half a century, our field tenaciously held to the monoamine theory, which posits that depression is caused by a deficiency of 5-HT or NE, or both. All antidepressants in use today were developed to increase brain mono­amines by inhibiting their reuptake at the synaptic cleft. Now, research points to other causes:
   • impaired neuroplasticity
   • a decrement of neurogenesis
   • synaptic deficits
   • decreased neurotrophins (such as brain-derived neurotrophic factor)
   • dendritic pathology.2,3


2. From ‘chemical imbalance’ to neuroinflammation

The simplistic notion that depression is a chemical imbalance, so to speak, in the brain is giving way to rapidly emerging evidence that depression is associated with neuroinflammation.4

Pro-inflammatory cytokines are elevated in the plasma of depressed patients, and subside when the acute episode is treated. Current antidepres­sants actually have anti-inflammatory effects that have gone unrecognized.5 A meta-analysis of the use of anti-inflammatory agents (such as nonste­roidal anti-inflammatory drugs and aspirin) in depression shows promising efficacy.6 Some inflammatory markers, such as C-reactive protein, already have been reported to predict response to some antidepressants, but not to others.7


3. From 5-HT and NE pathways to glutamate NMDA receptors

Recent landmark studies8 have, taken together, demonstrated that a single IV dose of the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine (a psychotogenic drug of abuse FDA-approved only as an anesthetic) can produce clinical improvement of severe depression and even full remission for several days. Such studies demonstrate that the old dogma of 5-HT and NE deficiency might not be a valid over­arching hypothesis of the depression syndrome.

Long-term maintenance studies of ketamine to document its safety and continued efficacy need to be con­ducted. The mechanism of action of ket­amine is believed to be a rapid trigger for enhancing neuroplasticity.


4. From oral to parenteral administration

Several studies have been published showing the efficacy of IV or intranasal administration of new agents for depres­sion. Ketamine studies, for example, were conducted using an IV infusion of a 150-mg dose over 1 hour. Other IV studies used the anticholinergic scopolamine.9

Intranasal ketamine also has been shown to be clinically efficacious.10 Inhalable nitrous oxide (laughing gas, an NMDA antagonist) recently was reported to improve depression as well.11

It is possible that parenteral admin­istration of antidepressant agents may exert a different neurobiological effect and provide a more rapid response than oral medication.


5. From delayed efficacy (weeks) to immediate onset (1 or 2 hours)

The widely entrenched notion that depression takes several weeks to improve with an antidepressant has collapsed with emerging evidence that symptoms of the disorder (even sui­cidal ideation) can be reversed within 1 or 2 hours.12 IV ketamine isn’t the only example; IV scopolamine,9 inhalable nitrous oxide,11 and overnight sleep deprivation13 also exert a rapid thera­peutic effect. This is a major rethinking of how quickly the curtain of severe depression can be lifted, and is great news for patients and their family.


6. From psychological symptoms to cortical or subcortical changes

Depression traditionally has been recog­nized as a clinical syndrome of sadness, self-deprecation, cognitive dulling, and vegetative symptoms. In recent stud­ies, however, researchers report that low hippocampus volume14 in healthy young girls predicts future depression. Patients with unremitting depression have been reported to have an abnor­mally shaped hippocampus.15

In addition, gray-matter volume in the subgenual anterior cingulate (Brodmann area 24) is hypoplastic in depressed persons,16 making that area a target for deep-brain stimulation (DBS). Brain morphological changes such as a hypoplastic hippocampus might become useful biomarkers for identify­ing persons at risk of severe depression, and might become a useful adjunc­tive biomarker for making a clinical diagnosis.

 

 


7. From healing the mind to repairing the brain

It is well-established that depression is associated with loss of dendritic spines and arborizations, loss of syn­apses, and diminishment of glial cells, especially in the hippocampus17 and anterior cingulate.18 Treating depression, whether pharmaceutical or somatic, involves reversing these changes by increasing neurotrophic factors, enhancing neurogenesis and gliogenesis, and restoring synaptic and dendritic health and cell survival in the hippocampus and frontal cor­tex.19,20 Treating depression involves brain repair, which is reflected, ulti­mately, in healing the mind.


8. From pharmacotherapy to neuromodulation

Although drugs remain the predomi­nant treatment modality for depression, there is palpable escalation in the use of neuromodulation methods.

The oldest of these neuromodulatory techniques is electroconvulsive ther­apy, an excellent treatment for severe depression (and one that enhances hip­pocampal neurogenesis). In addition, several novel neuromodulation meth­ods have been approved (transcranial magnetic stimulation and vagus nerve stimulation) or are in development (transcranial direct-current stimula­tion, cranial electrotherapy stimulation, and DBS).21 These somatic approaches to treating the brain directly to allevi­ate depression target regions involved in depression and reduce the needless risks associated with exposing other organ systems to a drug.


9. From monotherapy to combination therapy

The use of combination therapy for depression has escalated with FDA approval of adjunctive use of atypical antipsychotics in unipolar and bipolar depression. In addition, the landmark STAR*D study1 demonstrated the value of augmentation therapy with a second antidepressant when 1 agent fails. Other controlled studies have shown that combining 2 antidepressants is superior to administering 1.22

Just as other serious medical dis­orders—such as cancer and hyper­tension—are treated with 2 or 3 medications, severe depression might require a similar strategy. The field gradually is adopting that approach.


10. From cortical folds to wrinkles on the face
Last, a new (and unexpected) paradigm shift recently emerged, which is genu­inely intriguing—even baffling. Using placebo-controlled designs, several researchers have reported significant, persistent improvement of depressive symptoms after injection of onabotu­linumtoxinA in the corrugator muscles of the glabellar region of the face, where the omega sign often appears in a depressed person.23,24

The longest of the studies25 was 6 months; investigators reported that improvement continued even after the effect of the botulinum toxin on the omega sign wore off. The proposed mechanism of action is the facial feed­back hypothesis, which suggests that, biologically, facial expression has an impact on one’s emotional state.


Big payoffs coming from research in neuroscience

These 10 paradigm shifts in a single psychiatric syndrome are emblematic of exciting clinical and research advances in our field. Like all syndromes, depression is associated with multiple genetic and environmental causes; it isn’t surprising that myriad treatment approaches are emerging.

The days of clinging to monolithic, serendipity-generated models surely are over. Evidence-based psychiatric brain research is shattering aging dog­mas that have, for decades, stifled inno­vation in psychiatric therapeutics that is now moving in novel directions.

Take note, however, that the only par­adigm shift that matters to depressed patients is the one that transcends mere control of their symptoms and restores their wellness, functional capacity, and quality of life. With the explosive momentum of neuroscience discovery, psychiatry is, at last, poised to deliver—in splendid, even seismic, fashion.

Nowhere is that change in landscape more apparent than in major depression, the No. 1 disabling condition in all of medicine, according to the World Health Organization. The past decade has gen­erated at least 10 paradigm shifts in the neurobiology and pharmacotherapeutics of depression.


Clinging to simplistic tradition

Most contemporary clinicians con­tinue to practice the traditional model of depression, which is based on the assumption that depression is caused by a deficiency of monoamines: sero­tonin (5-HT) and norepinephrine (NE). The entire antidepressant armamentar­ium approved for use by the FDA was designed according to the amine defi­ciency hypothesis. Depressed patients uniformly receive reuptake inhibitors of 5-HT and NE, but few achieve full remission, as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed.1

As scientific paradigm shifts infil­trate clinical practice, however, the tired notion of “chemical imbalance” will yield to more complex and evidence-based models.

Usually, it would be remarkable to witness a single paradigm shift in the understanding of a brain disor­der. Imagine the disruptive impact of multiple scientific shifts within the past decade! Consider the follow­ing departures from the old dogma about the simplistic old explanation of depression.


1. From neurotransmitters to neuroplasticity

For half a century, our field tenaciously held to the monoamine theory, which posits that depression is caused by a deficiency of 5-HT or NE, or both. All antidepressants in use today were developed to increase brain mono­amines by inhibiting their reuptake at the synaptic cleft. Now, research points to other causes:
   • impaired neuroplasticity
   • a decrement of neurogenesis
   • synaptic deficits
   • decreased neurotrophins (such as brain-derived neurotrophic factor)
   • dendritic pathology.2,3


2. From ‘chemical imbalance’ to neuroinflammation

The simplistic notion that depression is a chemical imbalance, so to speak, in the brain is giving way to rapidly emerging evidence that depression is associated with neuroinflammation.4

Pro-inflammatory cytokines are elevated in the plasma of depressed patients, and subside when the acute episode is treated. Current antidepres­sants actually have anti-inflammatory effects that have gone unrecognized.5 A meta-analysis of the use of anti-inflammatory agents (such as nonste­roidal anti-inflammatory drugs and aspirin) in depression shows promising efficacy.6 Some inflammatory markers, such as C-reactive protein, already have been reported to predict response to some antidepressants, but not to others.7


3. From 5-HT and NE pathways to glutamate NMDA receptors

Recent landmark studies8 have, taken together, demonstrated that a single IV dose of the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine (a psychotogenic drug of abuse FDA-approved only as an anesthetic) can produce clinical improvement of severe depression and even full remission for several days. Such studies demonstrate that the old dogma of 5-HT and NE deficiency might not be a valid over­arching hypothesis of the depression syndrome.

Long-term maintenance studies of ketamine to document its safety and continued efficacy need to be con­ducted. The mechanism of action of ket­amine is believed to be a rapid trigger for enhancing neuroplasticity.


4. From oral to parenteral administration

Several studies have been published showing the efficacy of IV or intranasal administration of new agents for depres­sion. Ketamine studies, for example, were conducted using an IV infusion of a 150-mg dose over 1 hour. Other IV studies used the anticholinergic scopolamine.9

Intranasal ketamine also has been shown to be clinically efficacious.10 Inhalable nitrous oxide (laughing gas, an NMDA antagonist) recently was reported to improve depression as well.11

It is possible that parenteral admin­istration of antidepressant agents may exert a different neurobiological effect and provide a more rapid response than oral medication.


5. From delayed efficacy (weeks) to immediate onset (1 or 2 hours)

The widely entrenched notion that depression takes several weeks to improve with an antidepressant has collapsed with emerging evidence that symptoms of the disorder (even sui­cidal ideation) can be reversed within 1 or 2 hours.12 IV ketamine isn’t the only example; IV scopolamine,9 inhalable nitrous oxide,11 and overnight sleep deprivation13 also exert a rapid thera­peutic effect. This is a major rethinking of how quickly the curtain of severe depression can be lifted, and is great news for patients and their family.


6. From psychological symptoms to cortical or subcortical changes

Depression traditionally has been recog­nized as a clinical syndrome of sadness, self-deprecation, cognitive dulling, and vegetative symptoms. In recent stud­ies, however, researchers report that low hippocampus volume14 in healthy young girls predicts future depression. Patients with unremitting depression have been reported to have an abnor­mally shaped hippocampus.15

In addition, gray-matter volume in the subgenual anterior cingulate (Brodmann area 24) is hypoplastic in depressed persons,16 making that area a target for deep-brain stimulation (DBS). Brain morphological changes such as a hypoplastic hippocampus might become useful biomarkers for identify­ing persons at risk of severe depression, and might become a useful adjunc­tive biomarker for making a clinical diagnosis.

 

 


7. From healing the mind to repairing the brain

It is well-established that depression is associated with loss of dendritic spines and arborizations, loss of syn­apses, and diminishment of glial cells, especially in the hippocampus17 and anterior cingulate.18 Treating depression, whether pharmaceutical or somatic, involves reversing these changes by increasing neurotrophic factors, enhancing neurogenesis and gliogenesis, and restoring synaptic and dendritic health and cell survival in the hippocampus and frontal cor­tex.19,20 Treating depression involves brain repair, which is reflected, ulti­mately, in healing the mind.


8. From pharmacotherapy to neuromodulation

Although drugs remain the predomi­nant treatment modality for depression, there is palpable escalation in the use of neuromodulation methods.

The oldest of these neuromodulatory techniques is electroconvulsive ther­apy, an excellent treatment for severe depression (and one that enhances hip­pocampal neurogenesis). In addition, several novel neuromodulation meth­ods have been approved (transcranial magnetic stimulation and vagus nerve stimulation) or are in development (transcranial direct-current stimula­tion, cranial electrotherapy stimulation, and DBS).21 These somatic approaches to treating the brain directly to allevi­ate depression target regions involved in depression and reduce the needless risks associated with exposing other organ systems to a drug.


9. From monotherapy to combination therapy

The use of combination therapy for depression has escalated with FDA approval of adjunctive use of atypical antipsychotics in unipolar and bipolar depression. In addition, the landmark STAR*D study1 demonstrated the value of augmentation therapy with a second antidepressant when 1 agent fails. Other controlled studies have shown that combining 2 antidepressants is superior to administering 1.22

Just as other serious medical dis­orders—such as cancer and hyper­tension—are treated with 2 or 3 medications, severe depression might require a similar strategy. The field gradually is adopting that approach.


10. From cortical folds to wrinkles on the face
Last, a new (and unexpected) paradigm shift recently emerged, which is genu­inely intriguing—even baffling. Using placebo-controlled designs, several researchers have reported significant, persistent improvement of depressive symptoms after injection of onabotu­linumtoxinA in the corrugator muscles of the glabellar region of the face, where the omega sign often appears in a depressed person.23,24

The longest of the studies25 was 6 months; investigators reported that improvement continued even after the effect of the botulinum toxin on the omega sign wore off. The proposed mechanism of action is the facial feed­back hypothesis, which suggests that, biologically, facial expression has an impact on one’s emotional state.


Big payoffs coming from research in neuroscience

These 10 paradigm shifts in a single psychiatric syndrome are emblematic of exciting clinical and research advances in our field. Like all syndromes, depression is associated with multiple genetic and environmental causes; it isn’t surprising that myriad treatment approaches are emerging.

The days of clinging to monolithic, serendipity-generated models surely are over. Evidence-based psychiatric brain research is shattering aging dog­mas that have, for decades, stifled inno­vation in psychiatric therapeutics that is now moving in novel directions.

Take note, however, that the only par­adigm shift that matters to depressed patients is the one that transcends mere control of their symptoms and restores their wellness, functional capacity, and quality of life. With the explosive momentum of neuroscience discovery, psychiatry is, at last, poised to deliver—in splendid, even seismic, fashion.

References


1. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Eng J Med. 2006;354(12):1243-1252.
2. Serafini G, Hayley S, Pompili M, et al. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets [published online November 30, 2014]? CNS Neurol Disord Drug Targets. doi: 10.2174/1871527313666141130223723.
3. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
4. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105-114.
5. Sacre S, Medghalichi M, Gregory B, et al. Fluoxetine and citalopram exhibit potent anti-inflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010;62(3):683-693.
6. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
7. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortiptyline. Am J Psychiatry. 2014;171(14):1278-1286.
8. Abdallah CG, Sanacora G, Duman RS, et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics [published online October 17, 2014]. Annual Rev Med. doi: 10.1146/annurev-med-053013-062946.
9. Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35(12):2479-2488.
10. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014; 76(12):970-976.
11. Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial [published December 14, 2014]. Biol Psychiatry. doi: http://dx.doi.org/10.1016/j.biopsych.2014.11.016.
12. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
13. Bunney BG, Bunney WE. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol Psychiatry. 2013;73(12):1164-1171.
14. Chen MC, Hamilton JP, Gotlib IH. Decreased hippocampal volume in healthy girls at risk for depression. Arch Gen Psychiatry. 2010;67(3):270-276.
15. Tae WS, Kim SS, Lee KU, et al. Hippocampal shape deformation in female patients with unremitting major depressive disorder. AJNR Am J Neuroradiol. 2011;32(4):671-676.
16. Hamani C, Mayberg H, Synder B, et al. Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. J Neurosurg. 2009;111(6):1209-1215.
17. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518.
18. Redlich R, Almeoda JJ, Grotegerd D, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression. A voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 2014;71(11):1222-1230.
19. Mendez-David I, Hen R, Gardier AM, et al. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr. 2013;71(3):143-149.
20. Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2(3):49-57.
21. Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology. 2012;37(1):102-116.
22. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
23. Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574-581.
24. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014;52:1-6.
25. Magid M, Reichenberg JS, Poth PE, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837-844.

References


1. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Eng J Med. 2006;354(12):1243-1252.
2. Serafini G, Hayley S, Pompili M, et al. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets [published online November 30, 2014]? CNS Neurol Disord Drug Targets. doi: 10.2174/1871527313666141130223723.
3. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
4. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105-114.
5. Sacre S, Medghalichi M, Gregory B, et al. Fluoxetine and citalopram exhibit potent anti-inflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010;62(3):683-693.
6. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
7. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortiptyline. Am J Psychiatry. 2014;171(14):1278-1286.
8. Abdallah CG, Sanacora G, Duman RS, et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics [published online October 17, 2014]. Annual Rev Med. doi: 10.1146/annurev-med-053013-062946.
9. Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35(12):2479-2488.
10. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014; 76(12):970-976.
11. Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial [published December 14, 2014]. Biol Psychiatry. doi: http://dx.doi.org/10.1016/j.biopsych.2014.11.016.
12. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391.
13. Bunney BG, Bunney WE. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol Psychiatry. 2013;73(12):1164-1171.
14. Chen MC, Hamilton JP, Gotlib IH. Decreased hippocampal volume in healthy girls at risk for depression. Arch Gen Psychiatry. 2010;67(3):270-276.
15. Tae WS, Kim SS, Lee KU, et al. Hippocampal shape deformation in female patients with unremitting major depressive disorder. AJNR Am J Neuroradiol. 2011;32(4):671-676.
16. Hamani C, Mayberg H, Synder B, et al. Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. J Neurosurg. 2009;111(6):1209-1215.
17. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518.
18. Redlich R, Almeoda JJ, Grotegerd D, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression. A voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 2014;71(11):1222-1230.
19. Mendez-David I, Hen R, Gardier AM, et al. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr. 2013;71(3):143-149.
20. Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2(3):49-57.
21. Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology. 2012;37(1):102-116.
22. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
23. Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574-581.
24. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014;52:1-6.
25. Magid M, Reichenberg JS, Poth PE, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837-844.

Issue
Current Psychiatry - 14(2)
Issue
Current Psychiatry - 14(2)
Page Number
10-13
Page Number
10-13
Publications
Publications
Topics
Article Type
Display Headline
10 Recent paradigm shifts in the neurobiology and treatment of depression
Display Headline
10 Recent paradigm shifts in the neurobiology and treatment of depression
Legacy Keywords
neurobiology, depression, treatment of depression, psychopathology, changes in psychiatry, pharmacology, neuromodulation, monotherapy, combination therapy, neuroinflammation, neurotrasmitters, neuroplasticity
Legacy Keywords
neurobiology, depression, treatment of depression, psychopathology, changes in psychiatry, pharmacology, neuromodulation, monotherapy, combination therapy, neuroinflammation, neurotrasmitters, neuroplasticity
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Beware of methylmercury during pregnancy!

Article Type
Changed
Thu, 03/28/2019 - 15:32
Display Headline
Beware of methylmercury during pregnancy!

Dr. Henry A. Nasrallah is correct that wild salmon is a good choice for pregnant women who want to boost intake of omega-3 fatty acids (Current Psychiatry, Comments & Controversies, December 2014; pg 33 [http://bit.ly/1wQoXdP]). The main concern about fish intake during preg­nancy is exposure to methylmercury, and much of this concern is derived from the tragic results of epic mercury poisonings of food sources in the past.

The FDA advises that pregnant women and children avoid eat­ing shark, tilefish, king mackerel, and swordfish because these fish have a relatively high level of mer­cury.1 Fish that are low in methyl-mercury include salmon and canned light tuna. (More information is avail­able at http://www.fda.gov/Food/ResourcesForYou/HealthEducators/ucm083324.htm.)

Although wild fish tend to be higher in omega-3 fatty acids than farm-raised fish, farmed fish can be an excellent source of omega-3 fatty acids. This is analogous to eating farm-produced livestock vs free-range, grass-fed live­stock: Animals in their natural envi­ronment eat healthier and have more omega-3 fatty acids, whereas farmed livestock generally eat cheap and less healthy feed. Because wild fish can be pricey, it’s important that women understand that farm-raised fish are a good source of protein and other nutri­ents such as omega-3 fatty acids.

Research has been inconclusive regarding the antidepressant benefits of omega-3 fatty acids, with some, but not all, studies demonstrating an add-on benefit of omega-3 fatty acid supple­ments for mood disorders. However, several epidemiological studies have reported that the low quality of dietary intake of omega-3 fatty acids is associ­ated with psychiatric illness, and fish and seafood are sources of essential fatty acids and other nutrients.2

References


1. Food safety for moms-to-be: while you’re pregnant–methylmercury. U.S. Food and Drug Administration. http://www.fda.gov/Food/ ResourcesForYou/HealthEducators/ucm083324. htm. Updated October 30, 2014. Accessed January 5, 2015.
2. Quirk SE, Williams LJ, O’Neil A, et al. The association between diet quality, dietary patterns and depression in adults: a systematic review. BMC Psychiatry. 2013;13:175.

Article PDF
Author and Disclosure Information

Marlene P. Freeman, MD
Associate Professor of Psychiatry
Harvard Medical School
Associate Director
Perinatal and Reproductive Psychiatry Program
Medical Director
Clinical Trials Network & Institute
Massachusetts General Hospital Boston, Massachusetts

Issue
Current Psychiatry - 14(2)
Publications
Topics
Page Number
6
Legacy Keywords
pregnancy, pregnant, pregnant patient, recommending fish during pregnancy, can you eat fish when you're pregnant, methylmercury, eating fish during pregnancy
Sections
Author and Disclosure Information

Marlene P. Freeman, MD
Associate Professor of Psychiatry
Harvard Medical School
Associate Director
Perinatal and Reproductive Psychiatry Program
Medical Director
Clinical Trials Network & Institute
Massachusetts General Hospital Boston, Massachusetts

Author and Disclosure Information

Marlene P. Freeman, MD
Associate Professor of Psychiatry
Harvard Medical School
Associate Director
Perinatal and Reproductive Psychiatry Program
Medical Director
Clinical Trials Network & Institute
Massachusetts General Hospital Boston, Massachusetts

Article PDF
Article PDF
Related Articles

Dr. Henry A. Nasrallah is correct that wild salmon is a good choice for pregnant women who want to boost intake of omega-3 fatty acids (Current Psychiatry, Comments & Controversies, December 2014; pg 33 [http://bit.ly/1wQoXdP]). The main concern about fish intake during preg­nancy is exposure to methylmercury, and much of this concern is derived from the tragic results of epic mercury poisonings of food sources in the past.

The FDA advises that pregnant women and children avoid eat­ing shark, tilefish, king mackerel, and swordfish because these fish have a relatively high level of mer­cury.1 Fish that are low in methyl-mercury include salmon and canned light tuna. (More information is avail­able at http://www.fda.gov/Food/ResourcesForYou/HealthEducators/ucm083324.htm.)

Although wild fish tend to be higher in omega-3 fatty acids than farm-raised fish, farmed fish can be an excellent source of omega-3 fatty acids. This is analogous to eating farm-produced livestock vs free-range, grass-fed live­stock: Animals in their natural envi­ronment eat healthier and have more omega-3 fatty acids, whereas farmed livestock generally eat cheap and less healthy feed. Because wild fish can be pricey, it’s important that women understand that farm-raised fish are a good source of protein and other nutri­ents such as omega-3 fatty acids.

Research has been inconclusive regarding the antidepressant benefits of omega-3 fatty acids, with some, but not all, studies demonstrating an add-on benefit of omega-3 fatty acid supple­ments for mood disorders. However, several epidemiological studies have reported that the low quality of dietary intake of omega-3 fatty acids is associ­ated with psychiatric illness, and fish and seafood are sources of essential fatty acids and other nutrients.2

Dr. Henry A. Nasrallah is correct that wild salmon is a good choice for pregnant women who want to boost intake of omega-3 fatty acids (Current Psychiatry, Comments & Controversies, December 2014; pg 33 [http://bit.ly/1wQoXdP]). The main concern about fish intake during preg­nancy is exposure to methylmercury, and much of this concern is derived from the tragic results of epic mercury poisonings of food sources in the past.

The FDA advises that pregnant women and children avoid eat­ing shark, tilefish, king mackerel, and swordfish because these fish have a relatively high level of mer­cury.1 Fish that are low in methyl-mercury include salmon and canned light tuna. (More information is avail­able at http://www.fda.gov/Food/ResourcesForYou/HealthEducators/ucm083324.htm.)

Although wild fish tend to be higher in omega-3 fatty acids than farm-raised fish, farmed fish can be an excellent source of omega-3 fatty acids. This is analogous to eating farm-produced livestock vs free-range, grass-fed live­stock: Animals in their natural envi­ronment eat healthier and have more omega-3 fatty acids, whereas farmed livestock generally eat cheap and less healthy feed. Because wild fish can be pricey, it’s important that women understand that farm-raised fish are a good source of protein and other nutri­ents such as omega-3 fatty acids.

Research has been inconclusive regarding the antidepressant benefits of omega-3 fatty acids, with some, but not all, studies demonstrating an add-on benefit of omega-3 fatty acid supple­ments for mood disorders. However, several epidemiological studies have reported that the low quality of dietary intake of omega-3 fatty acids is associ­ated with psychiatric illness, and fish and seafood are sources of essential fatty acids and other nutrients.2

References


1. Food safety for moms-to-be: while you’re pregnant–methylmercury. U.S. Food and Drug Administration. http://www.fda.gov/Food/ ResourcesForYou/HealthEducators/ucm083324. htm. Updated October 30, 2014. Accessed January 5, 2015.
2. Quirk SE, Williams LJ, O’Neil A, et al. The association between diet quality, dietary patterns and depression in adults: a systematic review. BMC Psychiatry. 2013;13:175.

References


1. Food safety for moms-to-be: while you’re pregnant–methylmercury. U.S. Food and Drug Administration. http://www.fda.gov/Food/ ResourcesForYou/HealthEducators/ucm083324. htm. Updated October 30, 2014. Accessed January 5, 2015.
2. Quirk SE, Williams LJ, O’Neil A, et al. The association between diet quality, dietary patterns and depression in adults: a systematic review. BMC Psychiatry. 2013;13:175.

Issue
Current Psychiatry - 14(2)
Issue
Current Psychiatry - 14(2)
Page Number
6
Page Number
6
Publications
Publications
Topics
Article Type
Display Headline
Beware of methylmercury during pregnancy!
Display Headline
Beware of methylmercury during pregnancy!
Legacy Keywords
pregnancy, pregnant, pregnant patient, recommending fish during pregnancy, can you eat fish when you're pregnant, methylmercury, eating fish during pregnancy
Legacy Keywords
pregnancy, pregnant, pregnant patient, recommending fish during pregnancy, can you eat fish when you're pregnant, methylmercury, eating fish during pregnancy
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

More on insomnia disorders in older patients

Article Type
Changed
Mon, 04/16/2018 - 14:34
Display Headline
More on insomnia disorders in older patients

Regarding Drs. Irene S. Hong’s and Jeffrey R. Bishop’s article, “Sedative-hypnotics for sleepless geriatric patients: Choose wisely” (Current Psychiatry, 2014;13(10):36-39, 46-50, 52 [http://bit.ly/1ApmcoO]), which undertook a comprehensive review of current therapies for insom­nia in geriatric patients, here are 3 clarifications.
   • I want to reinforce the latest thinking about the nature and patho­physiology of insomnia. DSM-5 clas­sifies insomnia as a disorder, not as a symptom of other problems; the concept of “secondary insomnia” is rejected in DSM-5. Insomnia typically is seen as comorbid with other medi­cal and psychiatric disorders. Often, insomnia predates the comorbid dis­order (eg, depression), but rarely is it resolved by treating the comorbid condition.
   • Good clinical practice, therefore, requires treating the comorbid condi­tion and the insomnia each directly.
   • The insomnia disorder manifests itself, in part, by a report of difficulty falling asleep or staying asleep. The authors use the example of sleep-onset insomnia as typical in older adults. However, sleep maintenance and early morning awakenings are the most common symptoms among geriatric insomnia patients.
   • The authors mention only in passing an important medication for sleep maintenance in adults and in the geriatric patient specifically: doxepin. Low-dose doxepin, at 3 mg (for the geriatric patient) and 6 mg, is FDA-approved as a nonscheduled hypnotic for sleep maintenance insomnia. This formulationa is the only hypnotic clas­sified as safe for geriatric patients in the 2012 Beers Criteria Update of the American Geriatrics Society.1 Unlike higher dosages of doxepin, the action of low-dose doxepin is, essentially, selective H1 antagonism.

aSold as Silenor.

References

Reference
1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.

Article PDF
Author and Disclosure Information

Thomas Roth, PhD
Director, Sleep Disorders and Research Center
Henry Ford Hospital
Professor, Department of Psychiatry
Wayne State University School of Medicine
Detroit, Michigan
Clinical Professor, Department of Psychiatry
University of Michigan College of Medicine
Ann Arbor, Michigan

Issue
Current Psychiatry - 14(2)
Publications
Topics
Page Number
6
Legacy Keywords
insomnia, geriatric patients, sleepless geriatric patients, sleep disorders
Sections
Author and Disclosure Information

Thomas Roth, PhD
Director, Sleep Disorders and Research Center
Henry Ford Hospital
Professor, Department of Psychiatry
Wayne State University School of Medicine
Detroit, Michigan
Clinical Professor, Department of Psychiatry
University of Michigan College of Medicine
Ann Arbor, Michigan

Author and Disclosure Information

Thomas Roth, PhD
Director, Sleep Disorders and Research Center
Henry Ford Hospital
Professor, Department of Psychiatry
Wayne State University School of Medicine
Detroit, Michigan
Clinical Professor, Department of Psychiatry
University of Michigan College of Medicine
Ann Arbor, Michigan

Article PDF
Article PDF
Related Articles

Regarding Drs. Irene S. Hong’s and Jeffrey R. Bishop’s article, “Sedative-hypnotics for sleepless geriatric patients: Choose wisely” (Current Psychiatry, 2014;13(10):36-39, 46-50, 52 [http://bit.ly/1ApmcoO]), which undertook a comprehensive review of current therapies for insom­nia in geriatric patients, here are 3 clarifications.
   • I want to reinforce the latest thinking about the nature and patho­physiology of insomnia. DSM-5 clas­sifies insomnia as a disorder, not as a symptom of other problems; the concept of “secondary insomnia” is rejected in DSM-5. Insomnia typically is seen as comorbid with other medi­cal and psychiatric disorders. Often, insomnia predates the comorbid dis­order (eg, depression), but rarely is it resolved by treating the comorbid condition.
   • Good clinical practice, therefore, requires treating the comorbid condi­tion and the insomnia each directly.
   • The insomnia disorder manifests itself, in part, by a report of difficulty falling asleep or staying asleep. The authors use the example of sleep-onset insomnia as typical in older adults. However, sleep maintenance and early morning awakenings are the most common symptoms among geriatric insomnia patients.
   • The authors mention only in passing an important medication for sleep maintenance in adults and in the geriatric patient specifically: doxepin. Low-dose doxepin, at 3 mg (for the geriatric patient) and 6 mg, is FDA-approved as a nonscheduled hypnotic for sleep maintenance insomnia. This formulationa is the only hypnotic clas­sified as safe for geriatric patients in the 2012 Beers Criteria Update of the American Geriatrics Society.1 Unlike higher dosages of doxepin, the action of low-dose doxepin is, essentially, selective H1 antagonism.

aSold as Silenor.

Regarding Drs. Irene S. Hong’s and Jeffrey R. Bishop’s article, “Sedative-hypnotics for sleepless geriatric patients: Choose wisely” (Current Psychiatry, 2014;13(10):36-39, 46-50, 52 [http://bit.ly/1ApmcoO]), which undertook a comprehensive review of current therapies for insom­nia in geriatric patients, here are 3 clarifications.
   • I want to reinforce the latest thinking about the nature and patho­physiology of insomnia. DSM-5 clas­sifies insomnia as a disorder, not as a symptom of other problems; the concept of “secondary insomnia” is rejected in DSM-5. Insomnia typically is seen as comorbid with other medi­cal and psychiatric disorders. Often, insomnia predates the comorbid dis­order (eg, depression), but rarely is it resolved by treating the comorbid condition.
   • Good clinical practice, therefore, requires treating the comorbid condi­tion and the insomnia each directly.
   • The insomnia disorder manifests itself, in part, by a report of difficulty falling asleep or staying asleep. The authors use the example of sleep-onset insomnia as typical in older adults. However, sleep maintenance and early morning awakenings are the most common symptoms among geriatric insomnia patients.
   • The authors mention only in passing an important medication for sleep maintenance in adults and in the geriatric patient specifically: doxepin. Low-dose doxepin, at 3 mg (for the geriatric patient) and 6 mg, is FDA-approved as a nonscheduled hypnotic for sleep maintenance insomnia. This formulationa is the only hypnotic clas­sified as safe for geriatric patients in the 2012 Beers Criteria Update of the American Geriatrics Society.1 Unlike higher dosages of doxepin, the action of low-dose doxepin is, essentially, selective H1 antagonism.

aSold as Silenor.

References

Reference
1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.

References

Reference
1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.

Issue
Current Psychiatry - 14(2)
Issue
Current Psychiatry - 14(2)
Page Number
6
Page Number
6
Publications
Publications
Topics
Article Type
Display Headline
More on insomnia disorders in older patients
Display Headline
More on insomnia disorders in older patients
Legacy Keywords
insomnia, geriatric patients, sleepless geriatric patients, sleep disorders
Legacy Keywords
insomnia, geriatric patients, sleepless geriatric patients, sleep disorders
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Should the use of ‘endorse’ be endorsed in writing in psychiatry?

Article Type
Changed
Fri, 02/21/2020 - 12:07
Display Headline
Should the use of ‘endorse’ be endorsed in writing in psychiatry?

The word “endorse” often appears in the medical literature and is heard in oral presentations; psy­chiatrists use the term to mean that a person is reporting psychiatric symptoms or problems. However, such usage may be a stylistic catachresis—one that has the potential for misinterpretation or misunderstanding.


Finding ‘endorse’ in the psychiatric literature
We conducted a literature search to identify instances of “endorse” in schol­arly articles published in psychiatric journals between January 1, 2012, and November 25, 2013. Table 11-14 shows examples of typical uses of “endorse” in recent publications.


Even when “endorse” is used as a syn­onym for “report” or “describe,” use of the word in that context can seem out of place. We could not find any rationale in the medical literature for using “endorse” as a synonym for “report” or “describe.”

The definition of “endorse” in Merriam-Webster15 and Oxford Dictionaries16 includes:  
   • inscribing or signing a legal docu­ment, check, or bill  
   • approving or recommending an idea, product, or candidate.

We believe that using “endorse” in a psychiatric context could create confusion among medical trainees and professionals who are familiar with the correct meanings of the word.


Survey: Some residents use ‘endorse’ in oral presentations
We asked residents in the Department of Psychiatry at Drexel University College of Medicine to respond to a questionnaire regarding their understanding of the use of “endorse.” Their responses are summa­rized in Table 2.



What is wrong with using ‘endorse’? Except when “endorse” describes a patient formally affixing her (his) signature to a document for the purpose of (1) certifica­tion or (2) giving or showing one’s support for a cause, we think that use of the word in psychiatry is not in keeping with its formal, accepted definition. Furthermore, residents’ responses to our survey suggest that there is the danger of causing confu­sion in using the word“endorse” when “report” or “describe” is meant.

For example, if a patient “endorses” antisocial behavior, is she stating that she feels justified in exhibiting such behav­ior? Do students who “endorse” drug use approve of drug use? Another example: Youth who “endorse” gang member­ship have merely confirmed that they belonged to a gang at some time.

The intended meaning of “endorse” in these examples is probably closer to “admit” or “acknowledge.” The patient replies “yes” when the physician asks if she uses drugs or has had behavior problems; she is not nec­essarily recommending or approving these behaviors.

Usage is shifting. In the past, “complain” was common medical parlance for a patient’s report of symptoms or other health-related problems. In fact, medical, surgical, and psychiatric evaluations still begin with a “chief complaint” section. It’s possible that, because “complaint” might suggest that the patient is whining, the word fell out of favor in the medical lexicon and was replaced in the scholarly literature by the construction “the patient reports….”


Avoid jargon. Employ accurate terminology
We propose that “endorse,” like “complain,” is a cant of psychiatrists. We recommend that, when describing a patient’s statement or report of symptoms or experiences, prac­titioners should avoid “endorse” and write or say “report,” “express,” “exhibit,” or similar words. Using accurate terminology and avoiding imprecise or misleading jar­gon is not only linguistically appropriate but also can help avoid misunderstanding and improve patient care.


Acknowledgment
Diana Winters, Academic Publishing Services, Drexel University College of Medicine, provided editorial assistance in preparing the manuscript of this article and offered comment on the use of medical jargon.


Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry. 2012;169(4):364-373.
2. Thomas JJ, Weigel TJ, Lawton RK, et al. Cognitive-behavioral treatment of body image disturbance in a congenitally blind patient with anorexia nervosa. Am J Psychiatry. 2012;169(1):16-20.
3. Purcell B, Heisel MJ, Speice J, et al. Family connectedness moderates the association between living alone and suicide ideation in a clinical sample of adults 50 years and older. Am J Geriatr Psychiatry. 2012;20(8):717-723.
4. Dakin EK, Areán P. Patient perspectives on the benefits of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2013;21(2):155-163.
5. Mezuk B, Lohman M, Dumenci, L, et al. Are depression and frailty overlapping syndromes in mid- and late-life? A latent variable analysis. Am J Geriatr Psychiatry. 2013;21(6):560-569.
6. Boindala NS, Tucker P, Trautman RP. “Culture and psychiatry”: a course for second-year psychiatry residents. Acad Psychiatry. 2013;37(1):46-50.
7. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry. 2012;17(12):1186-1193.
8. Rodriguez CI, Kegeles LS, Levinson A, et al. A randomized controlled crossover trial of ketamine in obsessive-compulsive disorder (abstract W7). Neuropsychopharmacology. 2012;38:S317.
9. Whelan R, Garavan H. Fractionating the impulsivity construct in adolescence. Neuropsychopharmacology. 2013;38(1):250-251.
10. Rück C, Larsson KJ, Mataix-Cols D. Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012;22(6):406-414.
11. Mausbach BT, Chattillion EA, Roepke SK, et al. A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers. Am J Geriatr Psychiatry. 2013;21(1):5-13.
12. Peavy GM, Salmon DP, Edland SD, et al. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and “pure” Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(6):509-519.
13. Coid JW, Ullrich S, Keers R, et al. Gang membership, violence, and psychiatric morbidity. Am J Psychiatry. 2013;170(9):985-993.
14. Choi D, Tolova V, Socha E, et al. Substance use and attitudes on professional conduct among medical students: a single-institution study. Acad Psychiatry. 2013;37(3):191-195.
15. Endorse. Merriam-Webster. http://www.merriam-webster. com/dictionary/endorse. Accessed January 14, 2014.
16. Endorse. Oxford Dictionaries. http://www.oxforddictionaries. com/definition/english/endorse. Accessed January 14, 2014.

Article PDF
Author and Disclosure Information

John A. Gillean, MD
Adult Psychiatrist
Adult Recovery Services
Mental Health
Center of Denver
Denver, Colorado
He was a PGY-4, Department of Psychiatry, Drexel University College of Medicine, Philadelphia, Pennsylvania, when this article was written.


Rose Ries, MD
Clinical Associate Professor
Department of Psychiatry
Drexel University College of Medicine,
Philadelphia, Pennsylvania

 

Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Issue
Current Psychiatry - 14(1)
Publications
Topics
Page Number
e1-e3
Legacy Keywords
endorse, endorsing, lexicon, terminology, use of endorse
Sections
Author and Disclosure Information

John A. Gillean, MD
Adult Psychiatrist
Adult Recovery Services
Mental Health
Center of Denver
Denver, Colorado
He was a PGY-4, Department of Psychiatry, Drexel University College of Medicine, Philadelphia, Pennsylvania, when this article was written.


Rose Ries, MD
Clinical Associate Professor
Department of Psychiatry
Drexel University College of Medicine,
Philadelphia, Pennsylvania

 

Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Author and Disclosure Information

John A. Gillean, MD
Adult Psychiatrist
Adult Recovery Services
Mental Health
Center of Denver
Denver, Colorado
He was a PGY-4, Department of Psychiatry, Drexel University College of Medicine, Philadelphia, Pennsylvania, when this article was written.


Rose Ries, MD
Clinical Associate Professor
Department of Psychiatry
Drexel University College of Medicine,
Philadelphia, Pennsylvania

 

Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Article PDF
Article PDF

The word “endorse” often appears in the medical literature and is heard in oral presentations; psy­chiatrists use the term to mean that a person is reporting psychiatric symptoms or problems. However, such usage may be a stylistic catachresis—one that has the potential for misinterpretation or misunderstanding.


Finding ‘endorse’ in the psychiatric literature
We conducted a literature search to identify instances of “endorse” in schol­arly articles published in psychiatric journals between January 1, 2012, and November 25, 2013. Table 11-14 shows examples of typical uses of “endorse” in recent publications.


Even when “endorse” is used as a syn­onym for “report” or “describe,” use of the word in that context can seem out of place. We could not find any rationale in the medical literature for using “endorse” as a synonym for “report” or “describe.”

The definition of “endorse” in Merriam-Webster15 and Oxford Dictionaries16 includes:  
   • inscribing or signing a legal docu­ment, check, or bill  
   • approving or recommending an idea, product, or candidate.

We believe that using “endorse” in a psychiatric context could create confusion among medical trainees and professionals who are familiar with the correct meanings of the word.


Survey: Some residents use ‘endorse’ in oral presentations
We asked residents in the Department of Psychiatry at Drexel University College of Medicine to respond to a questionnaire regarding their understanding of the use of “endorse.” Their responses are summa­rized in Table 2.



What is wrong with using ‘endorse’? Except when “endorse” describes a patient formally affixing her (his) signature to a document for the purpose of (1) certifica­tion or (2) giving or showing one’s support for a cause, we think that use of the word in psychiatry is not in keeping with its formal, accepted definition. Furthermore, residents’ responses to our survey suggest that there is the danger of causing confu­sion in using the word“endorse” when “report” or “describe” is meant.

For example, if a patient “endorses” antisocial behavior, is she stating that she feels justified in exhibiting such behav­ior? Do students who “endorse” drug use approve of drug use? Another example: Youth who “endorse” gang member­ship have merely confirmed that they belonged to a gang at some time.

The intended meaning of “endorse” in these examples is probably closer to “admit” or “acknowledge.” The patient replies “yes” when the physician asks if she uses drugs or has had behavior problems; she is not nec­essarily recommending or approving these behaviors.

Usage is shifting. In the past, “complain” was common medical parlance for a patient’s report of symptoms or other health-related problems. In fact, medical, surgical, and psychiatric evaluations still begin with a “chief complaint” section. It’s possible that, because “complaint” might suggest that the patient is whining, the word fell out of favor in the medical lexicon and was replaced in the scholarly literature by the construction “the patient reports….”


Avoid jargon. Employ accurate terminology
We propose that “endorse,” like “complain,” is a cant of psychiatrists. We recommend that, when describing a patient’s statement or report of symptoms or experiences, prac­titioners should avoid “endorse” and write or say “report,” “express,” “exhibit,” or similar words. Using accurate terminology and avoiding imprecise or misleading jar­gon is not only linguistically appropriate but also can help avoid misunderstanding and improve patient care.


Acknowledgment
Diana Winters, Academic Publishing Services, Drexel University College of Medicine, provided editorial assistance in preparing the manuscript of this article and offered comment on the use of medical jargon.


Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

The word “endorse” often appears in the medical literature and is heard in oral presentations; psy­chiatrists use the term to mean that a person is reporting psychiatric symptoms or problems. However, such usage may be a stylistic catachresis—one that has the potential for misinterpretation or misunderstanding.


Finding ‘endorse’ in the psychiatric literature
We conducted a literature search to identify instances of “endorse” in schol­arly articles published in psychiatric journals between January 1, 2012, and November 25, 2013. Table 11-14 shows examples of typical uses of “endorse” in recent publications.


Even when “endorse” is used as a syn­onym for “report” or “describe,” use of the word in that context can seem out of place. We could not find any rationale in the medical literature for using “endorse” as a synonym for “report” or “describe.”

The definition of “endorse” in Merriam-Webster15 and Oxford Dictionaries16 includes:  
   • inscribing or signing a legal docu­ment, check, or bill  
   • approving or recommending an idea, product, or candidate.

We believe that using “endorse” in a psychiatric context could create confusion among medical trainees and professionals who are familiar with the correct meanings of the word.


Survey: Some residents use ‘endorse’ in oral presentations
We asked residents in the Department of Psychiatry at Drexel University College of Medicine to respond to a questionnaire regarding their understanding of the use of “endorse.” Their responses are summa­rized in Table 2.



What is wrong with using ‘endorse’? Except when “endorse” describes a patient formally affixing her (his) signature to a document for the purpose of (1) certifica­tion or (2) giving or showing one’s support for a cause, we think that use of the word in psychiatry is not in keeping with its formal, accepted definition. Furthermore, residents’ responses to our survey suggest that there is the danger of causing confu­sion in using the word“endorse” when “report” or “describe” is meant.

For example, if a patient “endorses” antisocial behavior, is she stating that she feels justified in exhibiting such behav­ior? Do students who “endorse” drug use approve of drug use? Another example: Youth who “endorse” gang member­ship have merely confirmed that they belonged to a gang at some time.

The intended meaning of “endorse” in these examples is probably closer to “admit” or “acknowledge.” The patient replies “yes” when the physician asks if she uses drugs or has had behavior problems; she is not nec­essarily recommending or approving these behaviors.

Usage is shifting. In the past, “complain” was common medical parlance for a patient’s report of symptoms or other health-related problems. In fact, medical, surgical, and psychiatric evaluations still begin with a “chief complaint” section. It’s possible that, because “complaint” might suggest that the patient is whining, the word fell out of favor in the medical lexicon and was replaced in the scholarly literature by the construction “the patient reports….”


Avoid jargon. Employ accurate terminology
We propose that “endorse,” like “complain,” is a cant of psychiatrists. We recommend that, when describing a patient’s statement or report of symptoms or experiences, prac­titioners should avoid “endorse” and write or say “report,” “express,” “exhibit,” or similar words. Using accurate terminology and avoiding imprecise or misleading jar­gon is not only linguistically appropriate but also can help avoid misunderstanding and improve patient care.


Acknowledgment
Diana Winters, Academic Publishing Services, Drexel University College of Medicine, provided editorial assistance in preparing the manuscript of this article and offered comment on the use of medical jargon.


Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry. 2012;169(4):364-373.
2. Thomas JJ, Weigel TJ, Lawton RK, et al. Cognitive-behavioral treatment of body image disturbance in a congenitally blind patient with anorexia nervosa. Am J Psychiatry. 2012;169(1):16-20.
3. Purcell B, Heisel MJ, Speice J, et al. Family connectedness moderates the association between living alone and suicide ideation in a clinical sample of adults 50 years and older. Am J Geriatr Psychiatry. 2012;20(8):717-723.
4. Dakin EK, Areán P. Patient perspectives on the benefits of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2013;21(2):155-163.
5. Mezuk B, Lohman M, Dumenci, L, et al. Are depression and frailty overlapping syndromes in mid- and late-life? A latent variable analysis. Am J Geriatr Psychiatry. 2013;21(6):560-569.
6. Boindala NS, Tucker P, Trautman RP. “Culture and psychiatry”: a course for second-year psychiatry residents. Acad Psychiatry. 2013;37(1):46-50.
7. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry. 2012;17(12):1186-1193.
8. Rodriguez CI, Kegeles LS, Levinson A, et al. A randomized controlled crossover trial of ketamine in obsessive-compulsive disorder (abstract W7). Neuropsychopharmacology. 2012;38:S317.
9. Whelan R, Garavan H. Fractionating the impulsivity construct in adolescence. Neuropsychopharmacology. 2013;38(1):250-251.
10. Rück C, Larsson KJ, Mataix-Cols D. Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012;22(6):406-414.
11. Mausbach BT, Chattillion EA, Roepke SK, et al. A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers. Am J Geriatr Psychiatry. 2013;21(1):5-13.
12. Peavy GM, Salmon DP, Edland SD, et al. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and “pure” Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(6):509-519.
13. Coid JW, Ullrich S, Keers R, et al. Gang membership, violence, and psychiatric morbidity. Am J Psychiatry. 2013;170(9):985-993.
14. Choi D, Tolova V, Socha E, et al. Substance use and attitudes on professional conduct among medical students: a single-institution study. Acad Psychiatry. 2013;37(3):191-195.
15. Endorse. Merriam-Webster. http://www.merriam-webster. com/dictionary/endorse. Accessed January 14, 2014.
16. Endorse. Oxford Dictionaries. http://www.oxforddictionaries. com/definition/english/endorse. Accessed January 14, 2014.

References


1. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry. 2012;169(4):364-373.
2. Thomas JJ, Weigel TJ, Lawton RK, et al. Cognitive-behavioral treatment of body image disturbance in a congenitally blind patient with anorexia nervosa. Am J Psychiatry. 2012;169(1):16-20.
3. Purcell B, Heisel MJ, Speice J, et al. Family connectedness moderates the association between living alone and suicide ideation in a clinical sample of adults 50 years and older. Am J Geriatr Psychiatry. 2012;20(8):717-723.
4. Dakin EK, Areán P. Patient perspectives on the benefits of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2013;21(2):155-163.
5. Mezuk B, Lohman M, Dumenci, L, et al. Are depression and frailty overlapping syndromes in mid- and late-life? A latent variable analysis. Am J Geriatr Psychiatry. 2013;21(6):560-569.
6. Boindala NS, Tucker P, Trautman RP. “Culture and psychiatry”: a course for second-year psychiatry residents. Acad Psychiatry. 2013;37(1):46-50.
7. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry. 2012;17(12):1186-1193.
8. Rodriguez CI, Kegeles LS, Levinson A, et al. A randomized controlled crossover trial of ketamine in obsessive-compulsive disorder (abstract W7). Neuropsychopharmacology. 2012;38:S317.
9. Whelan R, Garavan H. Fractionating the impulsivity construct in adolescence. Neuropsychopharmacology. 2013;38(1):250-251.
10. Rück C, Larsson KJ, Mataix-Cols D. Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012;22(6):406-414.
11. Mausbach BT, Chattillion EA, Roepke SK, et al. A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers. Am J Geriatr Psychiatry. 2013;21(1):5-13.
12. Peavy GM, Salmon DP, Edland SD, et al. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and “pure” Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(6):509-519.
13. Coid JW, Ullrich S, Keers R, et al. Gang membership, violence, and psychiatric morbidity. Am J Psychiatry. 2013;170(9):985-993.
14. Choi D, Tolova V, Socha E, et al. Substance use and attitudes on professional conduct among medical students: a single-institution study. Acad Psychiatry. 2013;37(3):191-195.
15. Endorse. Merriam-Webster. http://www.merriam-webster. com/dictionary/endorse. Accessed January 14, 2014.
16. Endorse. Oxford Dictionaries. http://www.oxforddictionaries. com/definition/english/endorse. Accessed January 14, 2014.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Page Number
e1-e3
Page Number
e1-e3
Publications
Publications
Topics
Article Type
Display Headline
Should the use of ‘endorse’ be endorsed in writing in psychiatry?
Display Headline
Should the use of ‘endorse’ be endorsed in writing in psychiatry?
Legacy Keywords
endorse, endorsing, lexicon, terminology, use of endorse
Legacy Keywords
endorse, endorsing, lexicon, terminology, use of endorse
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

‘Acting out’ or pathological?

Article Type
Changed
Mon, 10/05/2020 - 11:37
Display Headline
‘Acting out’ or pathological?

Author and Disclosure Information

Dr. Grant is Professor, Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, Illinois.

Issue
Current Psychiatry - 14(1)
Publications
Topics
Legacy Keywords
impulse control disorder, impulse-control disorder, acting out, misbehaving, pathological, adolescence, adolescent, teenager
Sections
Author and Disclosure Information

Dr. Grant is Professor, Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, Illinois.

Author and Disclosure Information

Dr. Grant is Professor, Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, Illinois.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Publications
Publications
Topics
Article Type
Display Headline
‘Acting out’ or pathological?
Display Headline
‘Acting out’ or pathological?
Legacy Keywords
impulse control disorder, impulse-control disorder, acting out, misbehaving, pathological, adolescence, adolescent, teenager
Legacy Keywords
impulse control disorder, impulse-control disorder, acting out, misbehaving, pathological, adolescence, adolescent, teenager
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article

Mental illness during pregnancy

Article Type
Changed
Thu, 03/28/2019 - 15:33
Display Headline
Mental illness during pregnancy

Author and Disclosure Information

 

Dr. Byatt is Assistant Professor of Psychiatry and Obstetrics and Gynecology, University of Massachusetts Medical School, and Psychiatrist, Psychosomatic Medicine, Women’s Mental Health Specialty Clinic, UMass Memorial Medical Center, Worcester, Massachusetts.

Issue
Current Psychiatry - 14(1)
Publications
Topics
Legacy Keywords
pregnant patients, pregnancy, mental illness during pregnancy, treating mental illness during pregnancy
Sections
Author and Disclosure Information

 

Dr. Byatt is Assistant Professor of Psychiatry and Obstetrics and Gynecology, University of Massachusetts Medical School, and Psychiatrist, Psychosomatic Medicine, Women’s Mental Health Specialty Clinic, UMass Memorial Medical Center, Worcester, Massachusetts.

Author and Disclosure Information

 

Dr. Byatt is Assistant Professor of Psychiatry and Obstetrics and Gynecology, University of Massachusetts Medical School, and Psychiatrist, Psychosomatic Medicine, Women’s Mental Health Specialty Clinic, UMass Memorial Medical Center, Worcester, Massachusetts.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Publications
Publications
Topics
Article Type
Display Headline
Mental illness during pregnancy
Display Headline
Mental illness during pregnancy
Legacy Keywords
pregnant patients, pregnancy, mental illness during pregnancy, treating mental illness during pregnancy
Legacy Keywords
pregnant patients, pregnancy, mental illness during pregnancy, treating mental illness during pregnancy
Sections
Disallow All Ads
Alternative CME
Use ProPublica

Consider a mandibular positioning device to alleviate sleep-disordered breathing

Article Type
Changed
Tue, 12/11/2018 - 15:18
Display Headline
Consider a mandibular positioning device to alleviate sleep-disordered breathing

Snoring, snorting, gasping, and obstruc­tive sleep apnea are caused by col­lapse of the pharyngeal airway during sleep.1 Pathophysiology includes a combi­nation of anatomical and physiological vari­ables.1 Common anatomical predisposing conditions include abnormalities of pharyn­geal, lingual, and dental arches; physiologi­cal concerns are advancing age, male sex, obesity, use of sedatives, body positioning, and reduced muscle tone during rapid eye movement sleep. Coexistence of anatomic and physiological elements can produce significant narrowing of the upper airway.

Comorbidities include vascular, meta­bolic, and psychiatric conditions. As many as one-third of people with symptoms of sleep apnea report depressed mood; approx­imately 10% of these patients meet criteria for moderate or severe depression.2

In short, sleep-disordered breathing has a globally negative effect on mental health.


When should you consider obtaining a sleep apnea study?

Refer patients for a sleep study when snor­ing, snorting, gasping, or pauses in breathing occur during sleep, or in the case of daytime sleepiness, fatigue, or unrefreshing sleep that cannot be explained by another medical or psychiatric illness.2 A sleep specialist can determine the most appropriate intervention for sleep-disordered breathing.

An apneic event is characterized by complete cessation of airflow; hypopnea is a partially compromised airway. In either event, at least a 3% decrease in oxygen saturation occurs for at least 10 seconds.3 A diagnosis of obstructive sleep apnea or hypopnea is required when polysomnography reveals either of:
   • ≥5 episodes of apnea or hypopnea, or both, per hour of sleep, with symptoms of a rhythmic breathing disturbance or daytime sleepiness or fatigue
   • ≥15 episodes of apnea or hypopnea, or both, per hour of sleep, regardless of accom­panying symptoms.2


What are the treatment options?
 
   • Continuous positive airway pressure (CPAP) machines.
   • Surgical procedures include adeno-tonsillectomy in children and surgical maxilla-mandibular advancement or pala­tal implants for adults.
   • A novel implantable electrical stimu­lation device stimulates the hypoglossal nerve, which activates the genioglossus muscle, thus moving the tongue forward to open the airway.
   • An anterior mandibular positioning (AMP) device increases the diameter of the retroglossal space by preventing posterior movement of the mandible and tongue, thereby limiting encroachment on the air­way diameter and reducing the potential for collapse.1-4


When should you recommend an AMP device?

Consider recommending an AMP device to treat sleep-disordered breathing when (1) lifestyle changes, such as sleep hygiene, weight loss, and stopping sedatives, do not work and (2) a CPAP machine or a surgical procedure is contraindicated or has been ineffective.1 An AMP device can minimize snoring and relieve airway obstruction, especially in patients with supine position-related apnea.4 To keep the airway open in non-supine position-related cases, an AMP device might be indicated in addition to CPAP delivered nasally.1

This plastic oral appliance is either a 1- or 2-piece design, and looks and is sized simi­larly to an athletic mouth-protection guard or an oral anti-bruxism tooth-protection appliance. It is affixed to the mandible and maxillary arches by clasps (Figure).




An AMP device often is most beneficial for supine-dependent sleep apnea patients and those with loud snoring, without sleep apnea.4 Response is best in young adults and in patients who have a low body mass index, are free of sedatives, and have appropriate cephalometrics of the oral, dental, or pha­ryngeal anatomy. Improved sleep architec­ture, continuous sleep with less snoring, and increased daytime alertness are observed in patients who respond to an AMP device.

An AMP device is contraindicated when the device cannot be affixed to the dental arches and in some patients with an anatom­ical or pain-related temporomandibular joint disorder.5 The device is easy to use, nonin­vasive, readily accessible, and less expensive than alternatives.3


How can you help maintain treatment adherence?
AMP devices can induce adverse effects, including dental pain or discomfort through orthodontic alterations; patient reports and follow-up can yield detection and device adjustments can alleviate such problems. Adherence generally is good, with complaints usually limited to minor tooth discomfort, occlusive changes, and increased or decreased salivation.5 In our clinical experience, many patients find these devices comfortable and easy to use, but might complain of feeling awkward when wearing them.

Changes in occlusion can occur during long-term treatment with an AMP device. Proper fitting is essential to facilitate a more open airway and the ability to speak and drink fluids, and to maintain safety, even if vomiting occurs while the device is in place.

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.
2. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. de Britto Teixeira AO, Abi-Ramia LB, de Oliveira Almeida MA. Treatment of obstructive sleep apnea with oral appliances. Prog Orthod. 2013;14:10.
4. Marklund M, Stenlund H, Franklin K. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest. 2004;125(4):1270-1278.
5. Ferguson KA, Cartwright R, Rogers R, et al. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep. 2006;29(2):244-262.

Article PDF
Author and Disclosure Information

Anoop Narahari, MD
Observer Physician

Shama Panjwani, MD
Observer Physician

Amandeep Bains, MD
Observer Physician

Steven Lippmann, MD
Professor
Department of Psychiatry and Behavioral Sciences
University of Louisville School of Medicine
Louisville, Kentucky

Issue
Current Psychiatry - 14(1)
Publications
Topics
Page Number
50-51
Legacy Keywords
mandibular positioning device, sleep-disordered breathing, sleep disordered breathing, sleep disorders, sleep apnea, snoring, snorting, gasping, obstructive sleep apnea
Sections
Author and Disclosure Information

Anoop Narahari, MD
Observer Physician

Shama Panjwani, MD
Observer Physician

Amandeep Bains, MD
Observer Physician

Steven Lippmann, MD
Professor
Department of Psychiatry and Behavioral Sciences
University of Louisville School of Medicine
Louisville, Kentucky

Author and Disclosure Information

Anoop Narahari, MD
Observer Physician

Shama Panjwani, MD
Observer Physician

Amandeep Bains, MD
Observer Physician

Steven Lippmann, MD
Professor
Department of Psychiatry and Behavioral Sciences
University of Louisville School of Medicine
Louisville, Kentucky

Article PDF
Article PDF

Snoring, snorting, gasping, and obstruc­tive sleep apnea are caused by col­lapse of the pharyngeal airway during sleep.1 Pathophysiology includes a combi­nation of anatomical and physiological vari­ables.1 Common anatomical predisposing conditions include abnormalities of pharyn­geal, lingual, and dental arches; physiologi­cal concerns are advancing age, male sex, obesity, use of sedatives, body positioning, and reduced muscle tone during rapid eye movement sleep. Coexistence of anatomic and physiological elements can produce significant narrowing of the upper airway.

Comorbidities include vascular, meta­bolic, and psychiatric conditions. As many as one-third of people with symptoms of sleep apnea report depressed mood; approx­imately 10% of these patients meet criteria for moderate or severe depression.2

In short, sleep-disordered breathing has a globally negative effect on mental health.


When should you consider obtaining a sleep apnea study?

Refer patients for a sleep study when snor­ing, snorting, gasping, or pauses in breathing occur during sleep, or in the case of daytime sleepiness, fatigue, or unrefreshing sleep that cannot be explained by another medical or psychiatric illness.2 A sleep specialist can determine the most appropriate intervention for sleep-disordered breathing.

An apneic event is characterized by complete cessation of airflow; hypopnea is a partially compromised airway. In either event, at least a 3% decrease in oxygen saturation occurs for at least 10 seconds.3 A diagnosis of obstructive sleep apnea or hypopnea is required when polysomnography reveals either of:
   • ≥5 episodes of apnea or hypopnea, or both, per hour of sleep, with symptoms of a rhythmic breathing disturbance or daytime sleepiness or fatigue
   • ≥15 episodes of apnea or hypopnea, or both, per hour of sleep, regardless of accom­panying symptoms.2


What are the treatment options?
 
   • Continuous positive airway pressure (CPAP) machines.
   • Surgical procedures include adeno-tonsillectomy in children and surgical maxilla-mandibular advancement or pala­tal implants for adults.
   • A novel implantable electrical stimu­lation device stimulates the hypoglossal nerve, which activates the genioglossus muscle, thus moving the tongue forward to open the airway.
   • An anterior mandibular positioning (AMP) device increases the diameter of the retroglossal space by preventing posterior movement of the mandible and tongue, thereby limiting encroachment on the air­way diameter and reducing the potential for collapse.1-4


When should you recommend an AMP device?

Consider recommending an AMP device to treat sleep-disordered breathing when (1) lifestyle changes, such as sleep hygiene, weight loss, and stopping sedatives, do not work and (2) a CPAP machine or a surgical procedure is contraindicated or has been ineffective.1 An AMP device can minimize snoring and relieve airway obstruction, especially in patients with supine position-related apnea.4 To keep the airway open in non-supine position-related cases, an AMP device might be indicated in addition to CPAP delivered nasally.1

This plastic oral appliance is either a 1- or 2-piece design, and looks and is sized simi­larly to an athletic mouth-protection guard or an oral anti-bruxism tooth-protection appliance. It is affixed to the mandible and maxillary arches by clasps (Figure).




An AMP device often is most beneficial for supine-dependent sleep apnea patients and those with loud snoring, without sleep apnea.4 Response is best in young adults and in patients who have a low body mass index, are free of sedatives, and have appropriate cephalometrics of the oral, dental, or pha­ryngeal anatomy. Improved sleep architec­ture, continuous sleep with less snoring, and increased daytime alertness are observed in patients who respond to an AMP device.

An AMP device is contraindicated when the device cannot be affixed to the dental arches and in some patients with an anatom­ical or pain-related temporomandibular joint disorder.5 The device is easy to use, nonin­vasive, readily accessible, and less expensive than alternatives.3


How can you help maintain treatment adherence?
AMP devices can induce adverse effects, including dental pain or discomfort through orthodontic alterations; patient reports and follow-up can yield detection and device adjustments can alleviate such problems. Adherence generally is good, with complaints usually limited to minor tooth discomfort, occlusive changes, and increased or decreased salivation.5 In our clinical experience, many patients find these devices comfortable and easy to use, but might complain of feeling awkward when wearing them.

Changes in occlusion can occur during long-term treatment with an AMP device. Proper fitting is essential to facilitate a more open airway and the ability to speak and drink fluids, and to maintain safety, even if vomiting occurs while the device is in place.

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

Snoring, snorting, gasping, and obstruc­tive sleep apnea are caused by col­lapse of the pharyngeal airway during sleep.1 Pathophysiology includes a combi­nation of anatomical and physiological vari­ables.1 Common anatomical predisposing conditions include abnormalities of pharyn­geal, lingual, and dental arches; physiologi­cal concerns are advancing age, male sex, obesity, use of sedatives, body positioning, and reduced muscle tone during rapid eye movement sleep. Coexistence of anatomic and physiological elements can produce significant narrowing of the upper airway.

Comorbidities include vascular, meta­bolic, and psychiatric conditions. As many as one-third of people with symptoms of sleep apnea report depressed mood; approx­imately 10% of these patients meet criteria for moderate or severe depression.2

In short, sleep-disordered breathing has a globally negative effect on mental health.


When should you consider obtaining a sleep apnea study?

Refer patients for a sleep study when snor­ing, snorting, gasping, or pauses in breathing occur during sleep, or in the case of daytime sleepiness, fatigue, or unrefreshing sleep that cannot be explained by another medical or psychiatric illness.2 A sleep specialist can determine the most appropriate intervention for sleep-disordered breathing.

An apneic event is characterized by complete cessation of airflow; hypopnea is a partially compromised airway. In either event, at least a 3% decrease in oxygen saturation occurs for at least 10 seconds.3 A diagnosis of obstructive sleep apnea or hypopnea is required when polysomnography reveals either of:
   • ≥5 episodes of apnea or hypopnea, or both, per hour of sleep, with symptoms of a rhythmic breathing disturbance or daytime sleepiness or fatigue
   • ≥15 episodes of apnea or hypopnea, or both, per hour of sleep, regardless of accom­panying symptoms.2


What are the treatment options?
 
   • Continuous positive airway pressure (CPAP) machines.
   • Surgical procedures include adeno-tonsillectomy in children and surgical maxilla-mandibular advancement or pala­tal implants for adults.
   • A novel implantable electrical stimu­lation device stimulates the hypoglossal nerve, which activates the genioglossus muscle, thus moving the tongue forward to open the airway.
   • An anterior mandibular positioning (AMP) device increases the diameter of the retroglossal space by preventing posterior movement of the mandible and tongue, thereby limiting encroachment on the air­way diameter and reducing the potential for collapse.1-4


When should you recommend an AMP device?

Consider recommending an AMP device to treat sleep-disordered breathing when (1) lifestyle changes, such as sleep hygiene, weight loss, and stopping sedatives, do not work and (2) a CPAP machine or a surgical procedure is contraindicated or has been ineffective.1 An AMP device can minimize snoring and relieve airway obstruction, especially in patients with supine position-related apnea.4 To keep the airway open in non-supine position-related cases, an AMP device might be indicated in addition to CPAP delivered nasally.1

This plastic oral appliance is either a 1- or 2-piece design, and looks and is sized simi­larly to an athletic mouth-protection guard or an oral anti-bruxism tooth-protection appliance. It is affixed to the mandible and maxillary arches by clasps (Figure).




An AMP device often is most beneficial for supine-dependent sleep apnea patients and those with loud snoring, without sleep apnea.4 Response is best in young adults and in patients who have a low body mass index, are free of sedatives, and have appropriate cephalometrics of the oral, dental, or pha­ryngeal anatomy. Improved sleep architec­ture, continuous sleep with less snoring, and increased daytime alertness are observed in patients who respond to an AMP device.

An AMP device is contraindicated when the device cannot be affixed to the dental arches and in some patients with an anatom­ical or pain-related temporomandibular joint disorder.5 The device is easy to use, nonin­vasive, readily accessible, and less expensive than alternatives.3


How can you help maintain treatment adherence?
AMP devices can induce adverse effects, including dental pain or discomfort through orthodontic alterations; patient reports and follow-up can yield detection and device adjustments can alleviate such problems. Adherence generally is good, with complaints usually limited to minor tooth discomfort, occlusive changes, and increased or decreased salivation.5 In our clinical experience, many patients find these devices comfortable and easy to use, but might complain of feeling awkward when wearing them.

Changes in occlusion can occur during long-term treatment with an AMP device. Proper fitting is essential to facilitate a more open airway and the ability to speak and drink fluids, and to maintain safety, even if vomiting occurs while the device is in place.

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.
2. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. de Britto Teixeira AO, Abi-Ramia LB, de Oliveira Almeida MA. Treatment of obstructive sleep apnea with oral appliances. Prog Orthod. 2013;14:10.
4. Marklund M, Stenlund H, Franklin K. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest. 2004;125(4):1270-1278.
5. Ferguson KA, Cartwright R, Rogers R, et al. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep. 2006;29(2):244-262.

References


1. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.
2. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. de Britto Teixeira AO, Abi-Ramia LB, de Oliveira Almeida MA. Treatment of obstructive sleep apnea with oral appliances. Prog Orthod. 2013;14:10.
4. Marklund M, Stenlund H, Franklin K. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest. 2004;125(4):1270-1278.
5. Ferguson KA, Cartwright R, Rogers R, et al. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep. 2006;29(2):244-262.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Page Number
50-51
Page Number
50-51
Publications
Publications
Topics
Article Type
Display Headline
Consider a mandibular positioning device to alleviate sleep-disordered breathing
Display Headline
Consider a mandibular positioning device to alleviate sleep-disordered breathing
Legacy Keywords
mandibular positioning device, sleep-disordered breathing, sleep disordered breathing, sleep disorders, sleep apnea, snoring, snorting, gasping, obstructive sleep apnea
Legacy Keywords
mandibular positioning device, sleep-disordered breathing, sleep disordered breathing, sleep disorders, sleep apnea, snoring, snorting, gasping, obstructive sleep apnea
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Young, pregnant, ataxic—and jilted

Article Type
Changed
Tue, 12/11/2018 - 15:29
Display Headline
Young, pregnant, ataxic—and jilted

CASE Difficulty walking
Ms. M, age 15, is a pregnant, Spanish-speaking Guatemalan woman who is brought to obstet­rics triage in a large academic medical center at 35 weeks gestational age. She complains of dizziness, tinnitus, left orbital headache, and difficulty walking.

The neurology service finds profound trun­cal ataxia, astasia-abasia, and buckling of the knees; a normal brain and spine MRI are not consistent with a neurologic etiology. Otolaryngology service evaluates Ms. M to rule out a cholesteatoma and suggests a head CT and endoscopy, which are normal.

Ms. M’s symptoms resolve after 3 days, although the gait disturbances persist. When no clear cause is found for her difficulty walk­ing, the psychiatry service is consulted to evalu­ate whether an underlying psychiatric disorder is contributing to symptoms.


What could be causing Ms. M’s symptoms?

   a) malingering
   b) factitious disorder
   c) undiagnosed neurologic disorder
   d) conversion disorder


The authors’ observations

Women are vulnerable to a variety of psy­chiatric illnesses during pregnancy1 that have deleterious effects on mother, baby, and family.2-6 Although there is a burgeoning literature on affective and anxiety disorders occurring in pregnancy, there is a dearth of information about somatoform disorders.


HISTORY
Abandonment

Ms. M reports that, although her boyfriend deserted her after learning about the unexpected pregnancy, she will welcome the baby and looks forward to motherhood. She seems unaware of the responsibilities of being a mother.

Ms. M acknowledges a history of depression and self-harm a few years earlier, yet says she feels better now and thinks that psychiatric care is unnecessary. Because she does not endorse a history of trauma or symptoms suggesting an affective, anxiety, or psychotic illness, the psy­chiatrist does not recommend treatment with psychotropic medication. 

At age 5, Ms. M’s parents sent her to the United States with her aunt, hoping that she would have a better life than she would have had in Guatemala. Her aunt reports that Ms. M initially had difficulty adjusting to life in the United States without her parents, yet she has made substantial strides over the years and is now quite accustomed to the country. Her aunt describes Ms. M as an independent high school student who earns good grades.

During the interview, the psychiatrist observes that Ms. M exhibits childlike manner­isms, including sleeping with stuffed toys and coloring in Disney books with crayons. She also is indifferent to her gait difficulty, pregnancy, and psychosocial stressors. Her affect is incon­sistent with the content of her speech and she is alexithymic.

Ms. M’s aunt reports that her niece is becom­ing more dependent on her, which is not con­sistent with her baseline. Her aunt also notes that several years earlier, Ms. M’s nephew was diagnosed with a cholesteatoma after he pre­sented with similar symptoms.

The combination of (1) Ms. M’s clinical pre­sentation, which was causing her significant impairment in her social functioning, (2) the incompatibility of symptoms with any recog­nized neurologic and medical disease, and (3) prior family experience with cholesteatoma leads the consulting psychiatrist to suspect conversion disorder. Ms. M’s alexithymia, indif­ference to her symptoms, and recent aban­donment by the baby’s father also support a conversion disorder diagnosis.

From a psychodynamic perspective, the ataxia appears to be her way of protecting her­self from the abandonment she is experiencing by being left again to “stand alone” by her boy­friend as she had been when her parents sent her to the United States. Her regressive behav­ior could be her way of securing her aunt’s love and support.


The authors’ observations
This is the first case of psychogenic gait dis­turbance during pregnancy described in the literature. Authors have reported on pseu­dotoxemia,7 hyperemesis gravidarum,8 and pesudocyesis,9 yet there is a paucity of infor­mation on psychogenic gait disturbance during pregnancy. Ms. M’s case elucidates many of the clinical quandaries that occur when managing psychiatric illness—and, more specifically, conversion disorder— during pregnancy. Many women are hesi­tant to seek psychiatric treatment during pregnancy because of shame, stigma, and fear of loss of personal or parental rights10,11; it is not surprising that emotionally dis­tressed women communicate their feel­ings or troubled thoughts through physical symptoms.


Likely diagnosis

Conversion disorder is the presence of neurologic symptoms in the absence of a neurologic diagnosis that fully explains those symptoms. Conversion disorder, previously known as hysteria, is called functional neurologic symptom disorder in DSM-5 (Box).12 Symptoms are not feigned; instead, they represent “conver­sion” of emotional distress into neurologic symptoms.13,14 Although misdiagnosing conversion disorder in patients with true neurologic disease is uncommon, clini­cians often are uncomfortable making the diagnosis until all medical causes have been ruled out.14 It is not always possible to find a psychological explanation for conversion disorder, but a history of child­hood abuse, particularly sexual abuse, could play a role.14




Because of the variety of presenta­tions, clinicians in all specialties should be familiar with somatoform disorders; this is especially important in obstetrics and gynecology because women are more likely than men to develop these disorders.15 It is important to consider that Ms. M is a teen­ager and somatoform disorders can present differently in adults. The diagnostic process should include a diligent somatic workup and a personal and social history to identify the patient’s developmental tasks, stressors, and coping style.15

 

 


How would you treat Ms. M?

   a) destigmatize psychiatric illness and provide psychoeducation regarding treat­ment benefits
   b) identify and treat any comorbid psychiat­ric disorders
   c) maintain a proactive and multidisci­plinary approach that includes assess­ment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy
  d) all of the above


TREATMENT
Close follow-up

The psychiatrist recommends continued close psychiatric follow-up as well as multidisci­plinary involvement, including physical ther­apy, neurology, and obstetrics.

Ms. M initially is resistant to psychiatric follow-up because she says that “people on the street” told her that, if she saw a psychia­trist, her baby would be taken away. After the psychiatrist explains that it is unlikely her baby would be taken away, Ms. M immediately appears relieved, smiles, and readily agrees to outpatient psychotherapy.

Over the next 24 hours, she continues to work with a physical therapist and her gait sig­nificantly improves. She is discharged home 2 days later with a walking aid (Zimmer frame) for assistance.

Four days later, however, Ms. M is readmit­ted with worsening ataxia. Her aunt reports that, at home, Ms. M’s regressed behaviors are worsening; she is sleeping in bed with her and had several episodes of enuresis at home.

Ms. M continues to deny psychiatric symp­toms or anxiety about the delivery. Although she shows some improvement when work­ing with physical therapists, they note that Ms. M is still unable to ambulate or stand on her own. The psychiatrist is increasingly con­cerned about her regressed behavior and con­tinued ataxia.

A family meeting is held and the psychia­trist and social worker educate Ms. M and her aunt about conversion disorder, including how some emotionally distressed women communicate their feelings or troubled thoughts through physical symptoms and how that may apply to Ms. M. During the meeting, the team also destigmatizes psy­chiatric illness and treatment and provides psychoeducation regarding its benefits. The psychiatrist and social worker also provide a psychodynamic interpretation that her ataxia could be a way of protecting herself against the abandonment she is experiencing by being left to “stand alone” by her boyfriend— as she had been when her parents sent her to the United States, and that her behavior could be her way of securing her aunt’s love and support.Ms. M and her aunt both readily agree with this interpretation. The aunt notes that her niece is more anxious about motherhood than she acknowledges and is concerned that Ms. M expects her to be the primary care­giver for the baby. Those present note that Ms. M is becoming increasingly dependent on her aunt, and that it is important for her to retain her independence, especially once she becomes a mother.

Ms. M immediately begins to display more affect; she smiles and reports feeling relieved. Similar to the previous admission, her gait sig­nificantly improves over the next 2 days and she is discharged home with a walking aid.


The authors’ observations

A broad differential diagnosis and early multidisciplinary involvement might facilitate earlier diagnosis and treatment.16 Assessment of psychosocial stressors in the patient’s personal and family life, includ­ing circumstances around the pregnancy and the meaning of motherhood, as well as investigation of what the patient may gain from the sick role, are paramount. In Ms. M’s case, cultural background, sepa­ration from her parents at a young age, and recent abandonment by her boyfriend have contributed to her inability to “stand alone,” which manifested as ataxia. Young age, regressed behavior, and her minimi­zation of stressors also point to her dif­ficulty acknowledging and coping with psychosocial stressors.

Successful delivery of the diagnosis is key to treatment success. After building a therapeutic alliance, a multidisciplinary discussion should take place that allows the patient to understand the diagnosis and treatment plan.17,18 The patient and family should be reassured that the fetus is healthy and all organic causes of symptoms have been investigated.17 Although man­agement of conversion disorder during pregnancy is similar to that in non-preg­nant women, several additional avenues of investigation should be considered:
   • Explore the psychodynamic basis of the disorder and the role of the pregnancy and motherhood.
   • Identify any comorbid psychiatric disorders, particularly those specific to pregnancy or the postpartum period.
   • Because of the shame and stigma associated with seeking psychiatric treat­ment during pregnancy,10,11 it is impera­tive to destigmatize treatment and provide psychoeducation regarding its benefits.

A treatment plan can then be developed that involves psychotherapy, psychoedu­cation, stress management, and, when appropriate, pharmacotherapy.17

Providing psychoeducation about postpartum depression and other perina­tal psychiatric illness could be beneficial. Physical therapy often is culturally accept­able and can help re-establish healthy patterns of motor function.19 Ms. M’s gait  showed some improvement with physical therapy as part of the multidisciplinary approach, which also should include a thorough medical workup. Appropriate psychiatric treatment can help patients give up the sick role and return to their previous level of functioning.17

 

 

Maintain close communication with the outpatient perinatal care team as they mon­itor the patient’s parenting capacity. The outpatient perinatal care team also should engage pregnant or postpartum women in prioritizing their emotional well-being and encourage outpatient mental health treatment. Despite a dearth of data on the regressive symptoms and prognosis for future pregnancies, it is important to mon­itor maternal capacity and discuss the pos­sibility of symptom recurrence.


OUTCOME
Healthy baby

Three days later, Ms. M returns in labor with improved gait yet still using a walking aid. She has a normal vaginal delivery of a healthy baby boy at 37 weeks’ gestational age.

After the birth, Ms. M reports feeling well and enjoying motherhood, and denies psy­chiatric symptoms. She is ambulating without assistance within hours of delivery. This spon­taneous resolution of symptoms could have been because of the psychodynamically ori­ented multidisciplinary approach to her care, which may have helped her realize that she did not have to “stand alone” as she embarked on motherhood.

Before being discharged home, Ms. M and her aunt meet with the inpatient obstetric social worker to assess Ms. M’s ability to care for the baby and discuss the importance of continued emotional support. The social worker does not contact the Department of Children and Families because Ms. M is walking independently and not endorsing or exhibiting regressive behaviors. Ms. M also reports that she will ask her aunt to take care of the baby should ataxia recur. Her aunt reassures the social workers that she will encourage Ms. M to attend outpatient psy­chotherapy and will contact the social worker if she becomes concerned about Ms. M’s or the baby’s well-being.

During her postpartum obstetric visit, Ms. M is walking independently and does not exhibit or endorse neurologic symptoms. The social worker provides psychoeducation about the importance of outpatient psycho­therapy and schedules an initial appointment; Ms. M does not attend outpatient psychother­apy after discharge.

Bottom Line
Consider conversion disorder in obstetric patients who present with ataxia without a neurologic cause. Management involves a proactive and multidisciplinary approach that includes a thorough medical workup and assessment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy. Early identification and delivery of the diagnosis, destigmatization, and provision of appropriate psychiatric treatment can facilitate treatment success.

Disclosures
Dr. Byatt has received grant funding/support for this project from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR000160. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Toor reports no financial relationships with any company whose products are mentioned in this article or manufacturers of competing products.

References


1. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.
2. Britton HL, Gronwaldt V, Britton JR. Maternal postpartum behaviors and mother-infant relationship during the first year of life. J Pediatr. 2001;138(6):905-909.
3. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115(8):1043-1051.
4. Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child language development. J Child Psychol Psychiatry. 2009;50(3):254-262.
5. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5 pt 1):1107-1111.
6. Forman DR, O’Hara MW, Stuart S, et al. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol. 2007;19(2):585-602.
7. Brady WJ Jr, Huff JS. Pseudotoxemia: new onset psychogenic seizure in third trimester pregnancy. J Emerg Med. 1997;15(6):815-820.
8. el-Mallakh RS, Liebowitz NR, Hale MS. Hyperemesis gravidarum as conversion disorder. J Nerv Ment Dis. 1990; 178(10):655-659.
9. Paulman PM, Sadat A. Pseudocyesis. J Fam Pract. 1990;30(5):575-576.
10. Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and maternal treatment p: a qualitative systematic review. Birth. 2006;33(4):323-331.
11. Byatt N, Simas TA, Lundquist RS, et al. Strategies for improving perinatal depression treatment in North American outpatient obstetric settings. J Psychosom Obstetr Gynaecol. 2012;33(4):143-161.
12. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
13. Feinstein A. Conversion disorder: advances in our understanding. CMAJ. 2011;183(8):915-920.
14. Nicholson TR, Stone J, Kanaan RA. Conversion disorder: a problematic diagnosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1267-1273.
15. Bitzer J. Somatization disorders in obstetrics and gynecology. Arch Womens Mental health, 2003;6(2):99-107.
16. Smith HE, Rynning RE, Okafor C, et al. Evaluation of neurologic deficit without apparent cause: the importance of a multidisciplinary approach. J Spinal Cord Med. 2007;30(5):509-517.
17. Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol. 2006;5(8):695-700.
18. Oyama O, Paltoo C, Greengold J. Somatoform disorders. Am Fam Physician. 2007;76(9):1333-1338.
19. Ness D. Physical therapy management for conversion disorder: case series. J Neurol Phys Ther. 2007;31(1):30-39.

Article PDF
Author and Disclosure Information

Nancy Byatt, DO, MBA
Assistant Professor of Psychiatry and Obstetrics and Gynecology
University of Massachusetts Medical School
Psychiatrist
Psychosomatic Medicine
Women’s Mental Health Specialty Clinic
UMass Memorial Medical Center
Worcester, Massachusetts


Ramanpreet Toor, MD
Acting Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, Washington

Issue
Current Psychiatry - 14(1)
Publications
Topics
Page Number
44-49
Legacy Keywords
pregnant, truncal ataxia, astasia-abasia, somatic disorders, conversion disorder, neurologic symptoms
Sections
Author and Disclosure Information

Nancy Byatt, DO, MBA
Assistant Professor of Psychiatry and Obstetrics and Gynecology
University of Massachusetts Medical School
Psychiatrist
Psychosomatic Medicine
Women’s Mental Health Specialty Clinic
UMass Memorial Medical Center
Worcester, Massachusetts


Ramanpreet Toor, MD
Acting Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, Washington

Author and Disclosure Information

Nancy Byatt, DO, MBA
Assistant Professor of Psychiatry and Obstetrics and Gynecology
University of Massachusetts Medical School
Psychiatrist
Psychosomatic Medicine
Women’s Mental Health Specialty Clinic
UMass Memorial Medical Center
Worcester, Massachusetts


Ramanpreet Toor, MD
Acting Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, Washington

Article PDF
Article PDF

CASE Difficulty walking
Ms. M, age 15, is a pregnant, Spanish-speaking Guatemalan woman who is brought to obstet­rics triage in a large academic medical center at 35 weeks gestational age. She complains of dizziness, tinnitus, left orbital headache, and difficulty walking.

The neurology service finds profound trun­cal ataxia, astasia-abasia, and buckling of the knees; a normal brain and spine MRI are not consistent with a neurologic etiology. Otolaryngology service evaluates Ms. M to rule out a cholesteatoma and suggests a head CT and endoscopy, which are normal.

Ms. M’s symptoms resolve after 3 days, although the gait disturbances persist. When no clear cause is found for her difficulty walk­ing, the psychiatry service is consulted to evalu­ate whether an underlying psychiatric disorder is contributing to symptoms.


What could be causing Ms. M’s symptoms?

   a) malingering
   b) factitious disorder
   c) undiagnosed neurologic disorder
   d) conversion disorder


The authors’ observations

Women are vulnerable to a variety of psy­chiatric illnesses during pregnancy1 that have deleterious effects on mother, baby, and family.2-6 Although there is a burgeoning literature on affective and anxiety disorders occurring in pregnancy, there is a dearth of information about somatoform disorders.


HISTORY
Abandonment

Ms. M reports that, although her boyfriend deserted her after learning about the unexpected pregnancy, she will welcome the baby and looks forward to motherhood. She seems unaware of the responsibilities of being a mother.

Ms. M acknowledges a history of depression and self-harm a few years earlier, yet says she feels better now and thinks that psychiatric care is unnecessary. Because she does not endorse a history of trauma or symptoms suggesting an affective, anxiety, or psychotic illness, the psy­chiatrist does not recommend treatment with psychotropic medication. 

At age 5, Ms. M’s parents sent her to the United States with her aunt, hoping that she would have a better life than she would have had in Guatemala. Her aunt reports that Ms. M initially had difficulty adjusting to life in the United States without her parents, yet she has made substantial strides over the years and is now quite accustomed to the country. Her aunt describes Ms. M as an independent high school student who earns good grades.

During the interview, the psychiatrist observes that Ms. M exhibits childlike manner­isms, including sleeping with stuffed toys and coloring in Disney books with crayons. She also is indifferent to her gait difficulty, pregnancy, and psychosocial stressors. Her affect is incon­sistent with the content of her speech and she is alexithymic.

Ms. M’s aunt reports that her niece is becom­ing more dependent on her, which is not con­sistent with her baseline. Her aunt also notes that several years earlier, Ms. M’s nephew was diagnosed with a cholesteatoma after he pre­sented with similar symptoms.

The combination of (1) Ms. M’s clinical pre­sentation, which was causing her significant impairment in her social functioning, (2) the incompatibility of symptoms with any recog­nized neurologic and medical disease, and (3) prior family experience with cholesteatoma leads the consulting psychiatrist to suspect conversion disorder. Ms. M’s alexithymia, indif­ference to her symptoms, and recent aban­donment by the baby’s father also support a conversion disorder diagnosis.

From a psychodynamic perspective, the ataxia appears to be her way of protecting her­self from the abandonment she is experiencing by being left again to “stand alone” by her boy­friend as she had been when her parents sent her to the United States. Her regressive behav­ior could be her way of securing her aunt’s love and support.


The authors’ observations
This is the first case of psychogenic gait dis­turbance during pregnancy described in the literature. Authors have reported on pseu­dotoxemia,7 hyperemesis gravidarum,8 and pesudocyesis,9 yet there is a paucity of infor­mation on psychogenic gait disturbance during pregnancy. Ms. M’s case elucidates many of the clinical quandaries that occur when managing psychiatric illness—and, more specifically, conversion disorder— during pregnancy. Many women are hesi­tant to seek psychiatric treatment during pregnancy because of shame, stigma, and fear of loss of personal or parental rights10,11; it is not surprising that emotionally dis­tressed women communicate their feel­ings or troubled thoughts through physical symptoms.


Likely diagnosis

Conversion disorder is the presence of neurologic symptoms in the absence of a neurologic diagnosis that fully explains those symptoms. Conversion disorder, previously known as hysteria, is called functional neurologic symptom disorder in DSM-5 (Box).12 Symptoms are not feigned; instead, they represent “conver­sion” of emotional distress into neurologic symptoms.13,14 Although misdiagnosing conversion disorder in patients with true neurologic disease is uncommon, clini­cians often are uncomfortable making the diagnosis until all medical causes have been ruled out.14 It is not always possible to find a psychological explanation for conversion disorder, but a history of child­hood abuse, particularly sexual abuse, could play a role.14




Because of the variety of presenta­tions, clinicians in all specialties should be familiar with somatoform disorders; this is especially important in obstetrics and gynecology because women are more likely than men to develop these disorders.15 It is important to consider that Ms. M is a teen­ager and somatoform disorders can present differently in adults. The diagnostic process should include a diligent somatic workup and a personal and social history to identify the patient’s developmental tasks, stressors, and coping style.15

 

 


How would you treat Ms. M?

   a) destigmatize psychiatric illness and provide psychoeducation regarding treat­ment benefits
   b) identify and treat any comorbid psychiat­ric disorders
   c) maintain a proactive and multidisci­plinary approach that includes assess­ment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy
  d) all of the above


TREATMENT
Close follow-up

The psychiatrist recommends continued close psychiatric follow-up as well as multidisci­plinary involvement, including physical ther­apy, neurology, and obstetrics.

Ms. M initially is resistant to psychiatric follow-up because she says that “people on the street” told her that, if she saw a psychia­trist, her baby would be taken away. After the psychiatrist explains that it is unlikely her baby would be taken away, Ms. M immediately appears relieved, smiles, and readily agrees to outpatient psychotherapy.

Over the next 24 hours, she continues to work with a physical therapist and her gait sig­nificantly improves. She is discharged home 2 days later with a walking aid (Zimmer frame) for assistance.

Four days later, however, Ms. M is readmit­ted with worsening ataxia. Her aunt reports that, at home, Ms. M’s regressed behaviors are worsening; she is sleeping in bed with her and had several episodes of enuresis at home.

Ms. M continues to deny psychiatric symp­toms or anxiety about the delivery. Although she shows some improvement when work­ing with physical therapists, they note that Ms. M is still unable to ambulate or stand on her own. The psychiatrist is increasingly con­cerned about her regressed behavior and con­tinued ataxia.

A family meeting is held and the psychia­trist and social worker educate Ms. M and her aunt about conversion disorder, including how some emotionally distressed women communicate their feelings or troubled thoughts through physical symptoms and how that may apply to Ms. M. During the meeting, the team also destigmatizes psy­chiatric illness and treatment and provides psychoeducation regarding its benefits. The psychiatrist and social worker also provide a psychodynamic interpretation that her ataxia could be a way of protecting herself against the abandonment she is experiencing by being left to “stand alone” by her boyfriend— as she had been when her parents sent her to the United States, and that her behavior could be her way of securing her aunt’s love and support.Ms. M and her aunt both readily agree with this interpretation. The aunt notes that her niece is more anxious about motherhood than she acknowledges and is concerned that Ms. M expects her to be the primary care­giver for the baby. Those present note that Ms. M is becoming increasingly dependent on her aunt, and that it is important for her to retain her independence, especially once she becomes a mother.

Ms. M immediately begins to display more affect; she smiles and reports feeling relieved. Similar to the previous admission, her gait sig­nificantly improves over the next 2 days and she is discharged home with a walking aid.


The authors’ observations

A broad differential diagnosis and early multidisciplinary involvement might facilitate earlier diagnosis and treatment.16 Assessment of psychosocial stressors in the patient’s personal and family life, includ­ing circumstances around the pregnancy and the meaning of motherhood, as well as investigation of what the patient may gain from the sick role, are paramount. In Ms. M’s case, cultural background, sepa­ration from her parents at a young age, and recent abandonment by her boyfriend have contributed to her inability to “stand alone,” which manifested as ataxia. Young age, regressed behavior, and her minimi­zation of stressors also point to her dif­ficulty acknowledging and coping with psychosocial stressors.

Successful delivery of the diagnosis is key to treatment success. After building a therapeutic alliance, a multidisciplinary discussion should take place that allows the patient to understand the diagnosis and treatment plan.17,18 The patient and family should be reassured that the fetus is healthy and all organic causes of symptoms have been investigated.17 Although man­agement of conversion disorder during pregnancy is similar to that in non-preg­nant women, several additional avenues of investigation should be considered:
   • Explore the psychodynamic basis of the disorder and the role of the pregnancy and motherhood.
   • Identify any comorbid psychiatric disorders, particularly those specific to pregnancy or the postpartum period.
   • Because of the shame and stigma associated with seeking psychiatric treat­ment during pregnancy,10,11 it is impera­tive to destigmatize treatment and provide psychoeducation regarding its benefits.

A treatment plan can then be developed that involves psychotherapy, psychoedu­cation, stress management, and, when appropriate, pharmacotherapy.17

Providing psychoeducation about postpartum depression and other perina­tal psychiatric illness could be beneficial. Physical therapy often is culturally accept­able and can help re-establish healthy patterns of motor function.19 Ms. M’s gait  showed some improvement with physical therapy as part of the multidisciplinary approach, which also should include a thorough medical workup. Appropriate psychiatric treatment can help patients give up the sick role and return to their previous level of functioning.17

 

 

Maintain close communication with the outpatient perinatal care team as they mon­itor the patient’s parenting capacity. The outpatient perinatal care team also should engage pregnant or postpartum women in prioritizing their emotional well-being and encourage outpatient mental health treatment. Despite a dearth of data on the regressive symptoms and prognosis for future pregnancies, it is important to mon­itor maternal capacity and discuss the pos­sibility of symptom recurrence.


OUTCOME
Healthy baby

Three days later, Ms. M returns in labor with improved gait yet still using a walking aid. She has a normal vaginal delivery of a healthy baby boy at 37 weeks’ gestational age.

After the birth, Ms. M reports feeling well and enjoying motherhood, and denies psy­chiatric symptoms. She is ambulating without assistance within hours of delivery. This spon­taneous resolution of symptoms could have been because of the psychodynamically ori­ented multidisciplinary approach to her care, which may have helped her realize that she did not have to “stand alone” as she embarked on motherhood.

Before being discharged home, Ms. M and her aunt meet with the inpatient obstetric social worker to assess Ms. M’s ability to care for the baby and discuss the importance of continued emotional support. The social worker does not contact the Department of Children and Families because Ms. M is walking independently and not endorsing or exhibiting regressive behaviors. Ms. M also reports that she will ask her aunt to take care of the baby should ataxia recur. Her aunt reassures the social workers that she will encourage Ms. M to attend outpatient psy­chotherapy and will contact the social worker if she becomes concerned about Ms. M’s or the baby’s well-being.

During her postpartum obstetric visit, Ms. M is walking independently and does not exhibit or endorse neurologic symptoms. The social worker provides psychoeducation about the importance of outpatient psycho­therapy and schedules an initial appointment; Ms. M does not attend outpatient psychother­apy after discharge.

Bottom Line
Consider conversion disorder in obstetric patients who present with ataxia without a neurologic cause. Management involves a proactive and multidisciplinary approach that includes a thorough medical workup and assessment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy. Early identification and delivery of the diagnosis, destigmatization, and provision of appropriate psychiatric treatment can facilitate treatment success.

Disclosures
Dr. Byatt has received grant funding/support for this project from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR000160. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Toor reports no financial relationships with any company whose products are mentioned in this article or manufacturers of competing products.

CASE Difficulty walking
Ms. M, age 15, is a pregnant, Spanish-speaking Guatemalan woman who is brought to obstet­rics triage in a large academic medical center at 35 weeks gestational age. She complains of dizziness, tinnitus, left orbital headache, and difficulty walking.

The neurology service finds profound trun­cal ataxia, astasia-abasia, and buckling of the knees; a normal brain and spine MRI are not consistent with a neurologic etiology. Otolaryngology service evaluates Ms. M to rule out a cholesteatoma and suggests a head CT and endoscopy, which are normal.

Ms. M’s symptoms resolve after 3 days, although the gait disturbances persist. When no clear cause is found for her difficulty walk­ing, the psychiatry service is consulted to evalu­ate whether an underlying psychiatric disorder is contributing to symptoms.


What could be causing Ms. M’s symptoms?

   a) malingering
   b) factitious disorder
   c) undiagnosed neurologic disorder
   d) conversion disorder


The authors’ observations

Women are vulnerable to a variety of psy­chiatric illnesses during pregnancy1 that have deleterious effects on mother, baby, and family.2-6 Although there is a burgeoning literature on affective and anxiety disorders occurring in pregnancy, there is a dearth of information about somatoform disorders.


HISTORY
Abandonment

Ms. M reports that, although her boyfriend deserted her after learning about the unexpected pregnancy, she will welcome the baby and looks forward to motherhood. She seems unaware of the responsibilities of being a mother.

Ms. M acknowledges a history of depression and self-harm a few years earlier, yet says she feels better now and thinks that psychiatric care is unnecessary. Because she does not endorse a history of trauma or symptoms suggesting an affective, anxiety, or psychotic illness, the psy­chiatrist does not recommend treatment with psychotropic medication. 

At age 5, Ms. M’s parents sent her to the United States with her aunt, hoping that she would have a better life than she would have had in Guatemala. Her aunt reports that Ms. M initially had difficulty adjusting to life in the United States without her parents, yet she has made substantial strides over the years and is now quite accustomed to the country. Her aunt describes Ms. M as an independent high school student who earns good grades.

During the interview, the psychiatrist observes that Ms. M exhibits childlike manner­isms, including sleeping with stuffed toys and coloring in Disney books with crayons. She also is indifferent to her gait difficulty, pregnancy, and psychosocial stressors. Her affect is incon­sistent with the content of her speech and she is alexithymic.

Ms. M’s aunt reports that her niece is becom­ing more dependent on her, which is not con­sistent with her baseline. Her aunt also notes that several years earlier, Ms. M’s nephew was diagnosed with a cholesteatoma after he pre­sented with similar symptoms.

The combination of (1) Ms. M’s clinical pre­sentation, which was causing her significant impairment in her social functioning, (2) the incompatibility of symptoms with any recog­nized neurologic and medical disease, and (3) prior family experience with cholesteatoma leads the consulting psychiatrist to suspect conversion disorder. Ms. M’s alexithymia, indif­ference to her symptoms, and recent aban­donment by the baby’s father also support a conversion disorder diagnosis.

From a psychodynamic perspective, the ataxia appears to be her way of protecting her­self from the abandonment she is experiencing by being left again to “stand alone” by her boy­friend as she had been when her parents sent her to the United States. Her regressive behav­ior could be her way of securing her aunt’s love and support.


The authors’ observations
This is the first case of psychogenic gait dis­turbance during pregnancy described in the literature. Authors have reported on pseu­dotoxemia,7 hyperemesis gravidarum,8 and pesudocyesis,9 yet there is a paucity of infor­mation on psychogenic gait disturbance during pregnancy. Ms. M’s case elucidates many of the clinical quandaries that occur when managing psychiatric illness—and, more specifically, conversion disorder— during pregnancy. Many women are hesi­tant to seek psychiatric treatment during pregnancy because of shame, stigma, and fear of loss of personal or parental rights10,11; it is not surprising that emotionally dis­tressed women communicate their feel­ings or troubled thoughts through physical symptoms.


Likely diagnosis

Conversion disorder is the presence of neurologic symptoms in the absence of a neurologic diagnosis that fully explains those symptoms. Conversion disorder, previously known as hysteria, is called functional neurologic symptom disorder in DSM-5 (Box).12 Symptoms are not feigned; instead, they represent “conver­sion” of emotional distress into neurologic symptoms.13,14 Although misdiagnosing conversion disorder in patients with true neurologic disease is uncommon, clini­cians often are uncomfortable making the diagnosis until all medical causes have been ruled out.14 It is not always possible to find a psychological explanation for conversion disorder, but a history of child­hood abuse, particularly sexual abuse, could play a role.14




Because of the variety of presenta­tions, clinicians in all specialties should be familiar with somatoform disorders; this is especially important in obstetrics and gynecology because women are more likely than men to develop these disorders.15 It is important to consider that Ms. M is a teen­ager and somatoform disorders can present differently in adults. The diagnostic process should include a diligent somatic workup and a personal and social history to identify the patient’s developmental tasks, stressors, and coping style.15

 

 


How would you treat Ms. M?

   a) destigmatize psychiatric illness and provide psychoeducation regarding treat­ment benefits
   b) identify and treat any comorbid psychiat­ric disorders
   c) maintain a proactive and multidisci­plinary approach that includes assess­ment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy
  d) all of the above


TREATMENT
Close follow-up

The psychiatrist recommends continued close psychiatric follow-up as well as multidisci­plinary involvement, including physical ther­apy, neurology, and obstetrics.

Ms. M initially is resistant to psychiatric follow-up because she says that “people on the street” told her that, if she saw a psychia­trist, her baby would be taken away. After the psychiatrist explains that it is unlikely her baby would be taken away, Ms. M immediately appears relieved, smiles, and readily agrees to outpatient psychotherapy.

Over the next 24 hours, she continues to work with a physical therapist and her gait sig­nificantly improves. She is discharged home 2 days later with a walking aid (Zimmer frame) for assistance.

Four days later, however, Ms. M is readmit­ted with worsening ataxia. Her aunt reports that, at home, Ms. M’s regressed behaviors are worsening; she is sleeping in bed with her and had several episodes of enuresis at home.

Ms. M continues to deny psychiatric symp­toms or anxiety about the delivery. Although she shows some improvement when work­ing with physical therapists, they note that Ms. M is still unable to ambulate or stand on her own. The psychiatrist is increasingly con­cerned about her regressed behavior and con­tinued ataxia.

A family meeting is held and the psychia­trist and social worker educate Ms. M and her aunt about conversion disorder, including how some emotionally distressed women communicate their feelings or troubled thoughts through physical symptoms and how that may apply to Ms. M. During the meeting, the team also destigmatizes psy­chiatric illness and treatment and provides psychoeducation regarding its benefits. The psychiatrist and social worker also provide a psychodynamic interpretation that her ataxia could be a way of protecting herself against the abandonment she is experiencing by being left to “stand alone” by her boyfriend— as she had been when her parents sent her to the United States, and that her behavior could be her way of securing her aunt’s love and support.Ms. M and her aunt both readily agree with this interpretation. The aunt notes that her niece is more anxious about motherhood than she acknowledges and is concerned that Ms. M expects her to be the primary care­giver for the baby. Those present note that Ms. M is becoming increasingly dependent on her aunt, and that it is important for her to retain her independence, especially once she becomes a mother.

Ms. M immediately begins to display more affect; she smiles and reports feeling relieved. Similar to the previous admission, her gait sig­nificantly improves over the next 2 days and she is discharged home with a walking aid.


The authors’ observations

A broad differential diagnosis and early multidisciplinary involvement might facilitate earlier diagnosis and treatment.16 Assessment of psychosocial stressors in the patient’s personal and family life, includ­ing circumstances around the pregnancy and the meaning of motherhood, as well as investigation of what the patient may gain from the sick role, are paramount. In Ms. M’s case, cultural background, sepa­ration from her parents at a young age, and recent abandonment by her boyfriend have contributed to her inability to “stand alone,” which manifested as ataxia. Young age, regressed behavior, and her minimi­zation of stressors also point to her dif­ficulty acknowledging and coping with psychosocial stressors.

Successful delivery of the diagnosis is key to treatment success. After building a therapeutic alliance, a multidisciplinary discussion should take place that allows the patient to understand the diagnosis and treatment plan.17,18 The patient and family should be reassured that the fetus is healthy and all organic causes of symptoms have been investigated.17 Although man­agement of conversion disorder during pregnancy is similar to that in non-preg­nant women, several additional avenues of investigation should be considered:
   • Explore the psychodynamic basis of the disorder and the role of the pregnancy and motherhood.
   • Identify any comorbid psychiatric disorders, particularly those specific to pregnancy or the postpartum period.
   • Because of the shame and stigma associated with seeking psychiatric treat­ment during pregnancy,10,11 it is impera­tive to destigmatize treatment and provide psychoeducation regarding its benefits.

A treatment plan can then be developed that involves psychotherapy, psychoedu­cation, stress management, and, when appropriate, pharmacotherapy.17

Providing psychoeducation about postpartum depression and other perina­tal psychiatric illness could be beneficial. Physical therapy often is culturally accept­able and can help re-establish healthy patterns of motor function.19 Ms. M’s gait  showed some improvement with physical therapy as part of the multidisciplinary approach, which also should include a thorough medical workup. Appropriate psychiatric treatment can help patients give up the sick role and return to their previous level of functioning.17

 

 

Maintain close communication with the outpatient perinatal care team as they mon­itor the patient’s parenting capacity. The outpatient perinatal care team also should engage pregnant or postpartum women in prioritizing their emotional well-being and encourage outpatient mental health treatment. Despite a dearth of data on the regressive symptoms and prognosis for future pregnancies, it is important to mon­itor maternal capacity and discuss the pos­sibility of symptom recurrence.


OUTCOME
Healthy baby

Three days later, Ms. M returns in labor with improved gait yet still using a walking aid. She has a normal vaginal delivery of a healthy baby boy at 37 weeks’ gestational age.

After the birth, Ms. M reports feeling well and enjoying motherhood, and denies psy­chiatric symptoms. She is ambulating without assistance within hours of delivery. This spon­taneous resolution of symptoms could have been because of the psychodynamically ori­ented multidisciplinary approach to her care, which may have helped her realize that she did not have to “stand alone” as she embarked on motherhood.

Before being discharged home, Ms. M and her aunt meet with the inpatient obstetric social worker to assess Ms. M’s ability to care for the baby and discuss the importance of continued emotional support. The social worker does not contact the Department of Children and Families because Ms. M is walking independently and not endorsing or exhibiting regressive behaviors. Ms. M also reports that she will ask her aunt to take care of the baby should ataxia recur. Her aunt reassures the social workers that she will encourage Ms. M to attend outpatient psy­chotherapy and will contact the social worker if she becomes concerned about Ms. M’s or the baby’s well-being.

During her postpartum obstetric visit, Ms. M is walking independently and does not exhibit or endorse neurologic symptoms. The social worker provides psychoeducation about the importance of outpatient psycho­therapy and schedules an initial appointment; Ms. M does not attend outpatient psychother­apy after discharge.

Bottom Line
Consider conversion disorder in obstetric patients who present with ataxia without a neurologic cause. Management involves a proactive and multidisciplinary approach that includes a thorough medical workup and assessment of psychosocial stressors and psychodynamic factors, particularly those related to the pregnancy. Early identification and delivery of the diagnosis, destigmatization, and provision of appropriate psychiatric treatment can facilitate treatment success.

Disclosures
Dr. Byatt has received grant funding/support for this project from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR000160. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Toor reports no financial relationships with any company whose products are mentioned in this article or manufacturers of competing products.

References


1. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.
2. Britton HL, Gronwaldt V, Britton JR. Maternal postpartum behaviors and mother-infant relationship during the first year of life. J Pediatr. 2001;138(6):905-909.
3. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115(8):1043-1051.
4. Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child language development. J Child Psychol Psychiatry. 2009;50(3):254-262.
5. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5 pt 1):1107-1111.
6. Forman DR, O’Hara MW, Stuart S, et al. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol. 2007;19(2):585-602.
7. Brady WJ Jr, Huff JS. Pseudotoxemia: new onset psychogenic seizure in third trimester pregnancy. J Emerg Med. 1997;15(6):815-820.
8. el-Mallakh RS, Liebowitz NR, Hale MS. Hyperemesis gravidarum as conversion disorder. J Nerv Ment Dis. 1990; 178(10):655-659.
9. Paulman PM, Sadat A. Pseudocyesis. J Fam Pract. 1990;30(5):575-576.
10. Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and maternal treatment p: a qualitative systematic review. Birth. 2006;33(4):323-331.
11. Byatt N, Simas TA, Lundquist RS, et al. Strategies for improving perinatal depression treatment in North American outpatient obstetric settings. J Psychosom Obstetr Gynaecol. 2012;33(4):143-161.
12. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
13. Feinstein A. Conversion disorder: advances in our understanding. CMAJ. 2011;183(8):915-920.
14. Nicholson TR, Stone J, Kanaan RA. Conversion disorder: a problematic diagnosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1267-1273.
15. Bitzer J. Somatization disorders in obstetrics and gynecology. Arch Womens Mental health, 2003;6(2):99-107.
16. Smith HE, Rynning RE, Okafor C, et al. Evaluation of neurologic deficit without apparent cause: the importance of a multidisciplinary approach. J Spinal Cord Med. 2007;30(5):509-517.
17. Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol. 2006;5(8):695-700.
18. Oyama O, Paltoo C, Greengold J. Somatoform disorders. Am Fam Physician. 2007;76(9):1333-1338.
19. Ness D. Physical therapy management for conversion disorder: case series. J Neurol Phys Ther. 2007;31(1):30-39.

References


1. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.
2. Britton HL, Gronwaldt V, Britton JR. Maternal postpartum behaviors and mother-infant relationship during the first year of life. J Pediatr. 2001;138(6):905-909.
3. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115(8):1043-1051.
4. Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child language development. J Child Psychol Psychiatry. 2009;50(3):254-262.
5. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5 pt 1):1107-1111.
6. Forman DR, O’Hara MW, Stuart S, et al. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol. 2007;19(2):585-602.
7. Brady WJ Jr, Huff JS. Pseudotoxemia: new onset psychogenic seizure in third trimester pregnancy. J Emerg Med. 1997;15(6):815-820.
8. el-Mallakh RS, Liebowitz NR, Hale MS. Hyperemesis gravidarum as conversion disorder. J Nerv Ment Dis. 1990; 178(10):655-659.
9. Paulman PM, Sadat A. Pseudocyesis. J Fam Pract. 1990;30(5):575-576.
10. Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and maternal treatment p: a qualitative systematic review. Birth. 2006;33(4):323-331.
11. Byatt N, Simas TA, Lundquist RS, et al. Strategies for improving perinatal depression treatment in North American outpatient obstetric settings. J Psychosom Obstetr Gynaecol. 2012;33(4):143-161.
12. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
13. Feinstein A. Conversion disorder: advances in our understanding. CMAJ. 2011;183(8):915-920.
14. Nicholson TR, Stone J, Kanaan RA. Conversion disorder: a problematic diagnosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1267-1273.
15. Bitzer J. Somatization disorders in obstetrics and gynecology. Arch Womens Mental health, 2003;6(2):99-107.
16. Smith HE, Rynning RE, Okafor C, et al. Evaluation of neurologic deficit without apparent cause: the importance of a multidisciplinary approach. J Spinal Cord Med. 2007;30(5):509-517.
17. Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol. 2006;5(8):695-700.
18. Oyama O, Paltoo C, Greengold J. Somatoform disorders. Am Fam Physician. 2007;76(9):1333-1338.
19. Ness D. Physical therapy management for conversion disorder: case series. J Neurol Phys Ther. 2007;31(1):30-39.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Page Number
44-49
Page Number
44-49
Publications
Publications
Topics
Article Type
Display Headline
Young, pregnant, ataxic—and jilted
Display Headline
Young, pregnant, ataxic—and jilted
Legacy Keywords
pregnant, truncal ataxia, astasia-abasia, somatic disorders, conversion disorder, neurologic symptoms
Legacy Keywords
pregnant, truncal ataxia, astasia-abasia, somatic disorders, conversion disorder, neurologic symptoms
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Have you RULED O2uT medical illness in the presumptive psychiatric patient?

Article Type
Changed
Tue, 12/11/2018 - 15:18
Display Headline
Have you RULED O2uT medical illness in the presumptive psychiatric patient?

What a practitioner might identify and report as “psychiatric” symp­toms or signs cannot always be explained in terms of psychological stress or a psychiatric disorder. In fact, a range of medical1 and neurologic2 illnesses can mani­fest in ways that appear psychiatric in nature. Common examples are sleep and thyroid dis­orders; deficiencies of vitamin D, folate, and B12; Parkinson’s disease; and anti-N-methyl-d-aspartate receptor autoimmune encephalitis.

People who have a medical illness with what appear to be psychiatric manifesta­tions often elude identification and diagno­sis because they do not visit a health care provider for any of several reasons, includ­ing difficulty obtaining health insurance. Instead, they might seek care in an emer­gency room (ER).

When such patients present for evalu­ation, it is easy—especially in a fast-paced ER—to miss the underlying cause of their illness. Some are then treated on the assump­tion that their diagnosis is psychiatric, while their medical illness goes unidentified.3

We propose a mnemonic, RULED O2uT, as a reminder in the ER (and any other set­ting) of the need to rule out physical illness before treating a patient for a psychiatric dis­order. To demonstrate how the work-up of a patient whose medical illness was obscured by psychiatric signs and symptoms could benefit from applying RULED O2uT, we also present a case.


CASE REPORT
A man with a medical illness who presented with psychiatric symptoms

Mr. Z, in his late 40s, is brought to the ER by his sister for evaluation of depressed mood of 6 to 8 months’ duration. He has no psychi­atric history.

On evaluation, Mr. Z does not remember an event or stressors that could have triggered depression. He describes complete loss of moti­vation for activities of daily living, such as per­sonal grooming. He has stopped leaving the house and meeting friends and family members.

Mr. Z’s sister is concerned for his well-being because he has been living without heat and electricity, which were disconnected for non­payment. Mr. Z reveals that he has not seen his primary care physician “for 20 or 25 years,” although he recently sought care in the ER of another hospital because of mild gait instabil­ity for several months.

Mr. Z has a blunted affect, with linear and goal-directed thought processes. He denies suicidal ideation. Laboratory testing, includ­ing a comprehensive metabolic panel, com­plete blood count, and urine toxicology and urinalysis, are negative.

A non-contrast CT scan of the head reveals foci of low attenuation in the left frontal corona radiata. Follow-up MRI of the brain, with and without contrast, shows extensive supratentorial and infratentorial demyelinat­ing lesions consistent with multiple sclerosis (MS). Several cerebral lesions in the white mat­ter are consistent with active demyelination.

Mr. Z is admitted to the neurology service and started on methylprednisolone for MS. The psychiatry consultation-liaison team pre­scribes sertraline, 50 mg titrated to 100 mg, for depression.

Detailed history means better overall evaluation
Mr. Z presented to the busy ER with psy­chiatric symptoms. It was easy to make a diagnosis of depression and refer him to the outpatient psychiatrist. However, a detailed history provided pertinent information about Mr. Z such as no regular medical check-ups, no family history of mental ill­ness, and gait disturbance in absence of physical injury. This enabled the physicians to conduct a thorough evaluation including a neurologic examination, laboratory tests, and imaging of the brain.


The 8 components of RULED O
2uT

Rx interactions. Review medications that the patient is taking or recently stopped tak­ing, to rule out drug−drug interactions and adverse effects.

Unusual presentation. Be mindful of any unusual presentation. For example, sud­den onset of psychiatric symptoms with seizures or hypersensitivity to the sun with depression or psychosis.

Labs. Obtain appropriate blood work, including:
   • comprehensive metabolic panel
   • complete blood count
   • thyroid-stimulating hormone (myx­edema, thyrotoxicosis)
   • delta-aminolevulinic acid and porpho­bilinogen (acute intermittent porphyria)
   • antinuclear antibody (systemic lupus erythematosus)
   • B12 level
   • fluorescent treponemal antibody absorption test (neurosyphilis)
   • serum ceruloplasmin and copper (Wilson’s disease).

Examination. Perform a thorough exami­nation, including a proper neurological exam. This is especially important when you see signs, or the patient reports symp­toms, that cannot be explained by depres­sion alone. An abnormality or change in gait, for example, might be a consequence of injury or a manifestation of MS, stroke, or Parkinson’s disease. Additional testing, such as CT of the head or lumbar puncture, might be appropriate to supplement or clar­ify findings of the exam. Mr. Z’s neurologic exam revealed weakness in his left leg with variability in reflexes.

Drugs. Ensure that a patient presenting with new-onset psychosis is not taking dopa­minergic medications or steroids and, based on results of a toxicology screen, is not under the influence of stimulants or hallucinogens.

Onset and Office. Determine:
   • the time since onset of symptoms; this is crucial to differentiate psychiatric disor­ders and ruling out a nonpsychiatric cause of the patient’s presentation
   • if the patient gets a regular medi­cal check-up with her (his) primary care physician.

 

 

Thorough history. Obtain a thorough his­tory so that you have a clear picture of the patient’s current situation; this includes medical history and family history of neu­rologic and psychiatric disorders and sub­stance abuse.
 

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Rahul R, Pieters T. An unusual psychiatric presentation of polycythaemia ‘Difficulties lie in our habits of thought rather than in the nature of things’ Andre Tardieu. BMJ Case Rep. 2013. pii: bcr2012008215. doi: 10.1136/bcr-2012-008215.
2. Butler C, Zeman AZ. Neurological syndromes which can be mistaken for psychiatric conditions. J Neurol Neurosurg Psychiatry. 2005;76(suppl 1):i31-i38.
3. Roie EV, Labarque V, Renard M, et al. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75(3):326-330.

Article PDF
Author and Disclosure Information

Anbreen Khizar, MD
PGY-3 Resident

Rashi Aggarwal, MD
Assistant Professor

Department of Psychiatry
Rutgers New Jersey Medical School
Newark, New Jersey

Issue
Current Psychiatry - 14(1)
Publications
Topics
Page Number
42-43
Legacy Keywords
psychiatric symptoms, medical illness, multiple sclerosis
Sections
Author and Disclosure Information

Anbreen Khizar, MD
PGY-3 Resident

Rashi Aggarwal, MD
Assistant Professor

Department of Psychiatry
Rutgers New Jersey Medical School
Newark, New Jersey

Author and Disclosure Information

Anbreen Khizar, MD
PGY-3 Resident

Rashi Aggarwal, MD
Assistant Professor

Department of Psychiatry
Rutgers New Jersey Medical School
Newark, New Jersey

Article PDF
Article PDF

What a practitioner might identify and report as “psychiatric” symp­toms or signs cannot always be explained in terms of psychological stress or a psychiatric disorder. In fact, a range of medical1 and neurologic2 illnesses can mani­fest in ways that appear psychiatric in nature. Common examples are sleep and thyroid dis­orders; deficiencies of vitamin D, folate, and B12; Parkinson’s disease; and anti-N-methyl-d-aspartate receptor autoimmune encephalitis.

People who have a medical illness with what appear to be psychiatric manifesta­tions often elude identification and diagno­sis because they do not visit a health care provider for any of several reasons, includ­ing difficulty obtaining health insurance. Instead, they might seek care in an emer­gency room (ER).

When such patients present for evalu­ation, it is easy—especially in a fast-paced ER—to miss the underlying cause of their illness. Some are then treated on the assump­tion that their diagnosis is psychiatric, while their medical illness goes unidentified.3

We propose a mnemonic, RULED O2uT, as a reminder in the ER (and any other set­ting) of the need to rule out physical illness before treating a patient for a psychiatric dis­order. To demonstrate how the work-up of a patient whose medical illness was obscured by psychiatric signs and symptoms could benefit from applying RULED O2uT, we also present a case.


CASE REPORT
A man with a medical illness who presented with psychiatric symptoms

Mr. Z, in his late 40s, is brought to the ER by his sister for evaluation of depressed mood of 6 to 8 months’ duration. He has no psychi­atric history.

On evaluation, Mr. Z does not remember an event or stressors that could have triggered depression. He describes complete loss of moti­vation for activities of daily living, such as per­sonal grooming. He has stopped leaving the house and meeting friends and family members.

Mr. Z’s sister is concerned for his well-being because he has been living without heat and electricity, which were disconnected for non­payment. Mr. Z reveals that he has not seen his primary care physician “for 20 or 25 years,” although he recently sought care in the ER of another hospital because of mild gait instabil­ity for several months.

Mr. Z has a blunted affect, with linear and goal-directed thought processes. He denies suicidal ideation. Laboratory testing, includ­ing a comprehensive metabolic panel, com­plete blood count, and urine toxicology and urinalysis, are negative.

A non-contrast CT scan of the head reveals foci of low attenuation in the left frontal corona radiata. Follow-up MRI of the brain, with and without contrast, shows extensive supratentorial and infratentorial demyelinat­ing lesions consistent with multiple sclerosis (MS). Several cerebral lesions in the white mat­ter are consistent with active demyelination.

Mr. Z is admitted to the neurology service and started on methylprednisolone for MS. The psychiatry consultation-liaison team pre­scribes sertraline, 50 mg titrated to 100 mg, for depression.

Detailed history means better overall evaluation
Mr. Z presented to the busy ER with psy­chiatric symptoms. It was easy to make a diagnosis of depression and refer him to the outpatient psychiatrist. However, a detailed history provided pertinent information about Mr. Z such as no regular medical check-ups, no family history of mental ill­ness, and gait disturbance in absence of physical injury. This enabled the physicians to conduct a thorough evaluation including a neurologic examination, laboratory tests, and imaging of the brain.


The 8 components of RULED O
2uT

Rx interactions. Review medications that the patient is taking or recently stopped tak­ing, to rule out drug−drug interactions and adverse effects.

Unusual presentation. Be mindful of any unusual presentation. For example, sud­den onset of psychiatric symptoms with seizures or hypersensitivity to the sun with depression or psychosis.

Labs. Obtain appropriate blood work, including:
   • comprehensive metabolic panel
   • complete blood count
   • thyroid-stimulating hormone (myx­edema, thyrotoxicosis)
   • delta-aminolevulinic acid and porpho­bilinogen (acute intermittent porphyria)
   • antinuclear antibody (systemic lupus erythematosus)
   • B12 level
   • fluorescent treponemal antibody absorption test (neurosyphilis)
   • serum ceruloplasmin and copper (Wilson’s disease).

Examination. Perform a thorough exami­nation, including a proper neurological exam. This is especially important when you see signs, or the patient reports symp­toms, that cannot be explained by depres­sion alone. An abnormality or change in gait, for example, might be a consequence of injury or a manifestation of MS, stroke, or Parkinson’s disease. Additional testing, such as CT of the head or lumbar puncture, might be appropriate to supplement or clar­ify findings of the exam. Mr. Z’s neurologic exam revealed weakness in his left leg with variability in reflexes.

Drugs. Ensure that a patient presenting with new-onset psychosis is not taking dopa­minergic medications or steroids and, based on results of a toxicology screen, is not under the influence of stimulants or hallucinogens.

Onset and Office. Determine:
   • the time since onset of symptoms; this is crucial to differentiate psychiatric disor­ders and ruling out a nonpsychiatric cause of the patient’s presentation
   • if the patient gets a regular medi­cal check-up with her (his) primary care physician.

 

 

Thorough history. Obtain a thorough his­tory so that you have a clear picture of the patient’s current situation; this includes medical history and family history of neu­rologic and psychiatric disorders and sub­stance abuse.
 

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

What a practitioner might identify and report as “psychiatric” symp­toms or signs cannot always be explained in terms of psychological stress or a psychiatric disorder. In fact, a range of medical1 and neurologic2 illnesses can mani­fest in ways that appear psychiatric in nature. Common examples are sleep and thyroid dis­orders; deficiencies of vitamin D, folate, and B12; Parkinson’s disease; and anti-N-methyl-d-aspartate receptor autoimmune encephalitis.

People who have a medical illness with what appear to be psychiatric manifesta­tions often elude identification and diagno­sis because they do not visit a health care provider for any of several reasons, includ­ing difficulty obtaining health insurance. Instead, they might seek care in an emer­gency room (ER).

When such patients present for evalu­ation, it is easy—especially in a fast-paced ER—to miss the underlying cause of their illness. Some are then treated on the assump­tion that their diagnosis is psychiatric, while their medical illness goes unidentified.3

We propose a mnemonic, RULED O2uT, as a reminder in the ER (and any other set­ting) of the need to rule out physical illness before treating a patient for a psychiatric dis­order. To demonstrate how the work-up of a patient whose medical illness was obscured by psychiatric signs and symptoms could benefit from applying RULED O2uT, we also present a case.


CASE REPORT
A man with a medical illness who presented with psychiatric symptoms

Mr. Z, in his late 40s, is brought to the ER by his sister for evaluation of depressed mood of 6 to 8 months’ duration. He has no psychi­atric history.

On evaluation, Mr. Z does not remember an event or stressors that could have triggered depression. He describes complete loss of moti­vation for activities of daily living, such as per­sonal grooming. He has stopped leaving the house and meeting friends and family members.

Mr. Z’s sister is concerned for his well-being because he has been living without heat and electricity, which were disconnected for non­payment. Mr. Z reveals that he has not seen his primary care physician “for 20 or 25 years,” although he recently sought care in the ER of another hospital because of mild gait instabil­ity for several months.

Mr. Z has a blunted affect, with linear and goal-directed thought processes. He denies suicidal ideation. Laboratory testing, includ­ing a comprehensive metabolic panel, com­plete blood count, and urine toxicology and urinalysis, are negative.

A non-contrast CT scan of the head reveals foci of low attenuation in the left frontal corona radiata. Follow-up MRI of the brain, with and without contrast, shows extensive supratentorial and infratentorial demyelinat­ing lesions consistent with multiple sclerosis (MS). Several cerebral lesions in the white mat­ter are consistent with active demyelination.

Mr. Z is admitted to the neurology service and started on methylprednisolone for MS. The psychiatry consultation-liaison team pre­scribes sertraline, 50 mg titrated to 100 mg, for depression.

Detailed history means better overall evaluation
Mr. Z presented to the busy ER with psy­chiatric symptoms. It was easy to make a diagnosis of depression and refer him to the outpatient psychiatrist. However, a detailed history provided pertinent information about Mr. Z such as no regular medical check-ups, no family history of mental ill­ness, and gait disturbance in absence of physical injury. This enabled the physicians to conduct a thorough evaluation including a neurologic examination, laboratory tests, and imaging of the brain.


The 8 components of RULED O
2uT

Rx interactions. Review medications that the patient is taking or recently stopped tak­ing, to rule out drug−drug interactions and adverse effects.

Unusual presentation. Be mindful of any unusual presentation. For example, sud­den onset of psychiatric symptoms with seizures or hypersensitivity to the sun with depression or psychosis.

Labs. Obtain appropriate blood work, including:
   • comprehensive metabolic panel
   • complete blood count
   • thyroid-stimulating hormone (myx­edema, thyrotoxicosis)
   • delta-aminolevulinic acid and porpho­bilinogen (acute intermittent porphyria)
   • antinuclear antibody (systemic lupus erythematosus)
   • B12 level
   • fluorescent treponemal antibody absorption test (neurosyphilis)
   • serum ceruloplasmin and copper (Wilson’s disease).

Examination. Perform a thorough exami­nation, including a proper neurological exam. This is especially important when you see signs, or the patient reports symp­toms, that cannot be explained by depres­sion alone. An abnormality or change in gait, for example, might be a consequence of injury or a manifestation of MS, stroke, or Parkinson’s disease. Additional testing, such as CT of the head or lumbar puncture, might be appropriate to supplement or clar­ify findings of the exam. Mr. Z’s neurologic exam revealed weakness in his left leg with variability in reflexes.

Drugs. Ensure that a patient presenting with new-onset psychosis is not taking dopa­minergic medications or steroids and, based on results of a toxicology screen, is not under the influence of stimulants or hallucinogens.

Onset and Office. Determine:
   • the time since onset of symptoms; this is crucial to differentiate psychiatric disor­ders and ruling out a nonpsychiatric cause of the patient’s presentation
   • if the patient gets a regular medi­cal check-up with her (his) primary care physician.

 

 

Thorough history. Obtain a thorough his­tory so that you have a clear picture of the patient’s current situation; this includes medical history and family history of neu­rologic and psychiatric disorders and sub­stance abuse.
 

Disclosures
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Rahul R, Pieters T. An unusual psychiatric presentation of polycythaemia ‘Difficulties lie in our habits of thought rather than in the nature of things’ Andre Tardieu. BMJ Case Rep. 2013. pii: bcr2012008215. doi: 10.1136/bcr-2012-008215.
2. Butler C, Zeman AZ. Neurological syndromes which can be mistaken for psychiatric conditions. J Neurol Neurosurg Psychiatry. 2005;76(suppl 1):i31-i38.
3. Roie EV, Labarque V, Renard M, et al. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75(3):326-330.

References


1. Rahul R, Pieters T. An unusual psychiatric presentation of polycythaemia ‘Difficulties lie in our habits of thought rather than in the nature of things’ Andre Tardieu. BMJ Case Rep. 2013. pii: bcr2012008215. doi: 10.1136/bcr-2012-008215.
2. Butler C, Zeman AZ. Neurological syndromes which can be mistaken for psychiatric conditions. J Neurol Neurosurg Psychiatry. 2005;76(suppl 1):i31-i38.
3. Roie EV, Labarque V, Renard M, et al. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75(3):326-330.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Page Number
42-43
Page Number
42-43
Publications
Publications
Topics
Article Type
Display Headline
Have you RULED O2uT medical illness in the presumptive psychiatric patient?
Display Headline
Have you RULED O2uT medical illness in the presumptive psychiatric patient?
Legacy Keywords
psychiatric symptoms, medical illness, multiple sclerosis
Legacy Keywords
psychiatric symptoms, medical illness, multiple sclerosis
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Second of 2 parts: The mysteries of psychiatry maintenance of certification, further unraveled

Article Type
Changed
Thu, 03/28/2019 - 15:33
Display Headline
Second of 2 parts: The mysteries of psychiatry maintenance of certification, further unraveled

To recap what I discussed in Part 1 of this article (December 2014): As part of a trend across all medical specialty boards, the American Board of Psychiatry and Neurology (ABPN) instituted a recertification pro­cess for all new general psychiatry certifications, starting October 1, 1994.1 In 2000, the specialties that comprise the American Board of Medical Specialties (ABMS) agreed to develop a comprehensive maintenance of certification (MOC) process to demonstrate ongoing learning and com­petency beyond what can be captured by a recertification examination. All ABMS member boards now use a 4-part process for recertification.

A great deal of professional and personal importance has been attached to maintaining one’s general and sub­specialty certifications. To that end, the 2 parts of this article highlight current ABPN MOC requirements and provide resources for understanding, tracking, and completing the self-assessment (SA) and performance-in-practice (PIP) components.

In this installment, I examine 3 components of MOC:
   • continuing medical education (CME), including SA requirements
   • improvement in medical practice (PIP)
   • continuous maintenance of certification (C-MOC)

In addition to this review, all physicians who are subject to MOC should download and read the 20-page revised MOC Program booklet v. 2.1 (May 2014).2

Continuing medical education
The CME requirement is clear: All diplo­mate physicians must accrue, on average, 30 Category-1 CME credits a year; the CME must be relevant to the specialty or subspecialty in which the diplomate prac­tices.3 For physicians who hold >1 ABPN certificates, the total CME requirement is the same; CME credits can be applied across each specialty and subspecialty.

The May 2014 MOC revision states that, for physicians who certified or recertified between 2005 and 2011 and who applied for the 2015 examination in 2014, the required CME credit total is 270.2 For all subsequent years of certification or recertification, including 2012, diplomates are enrolled in C-MOC, which is described below.2

To even out the accrual of CME credits across the prior 10 years, ABPN mandates that, for diplomates who certified or recer­tified between 2005 and 2011, one hundred fifty of the CME credits be accrued in the 5 years before they apply for the examina­tion. Diplomates in C-MOC should accrue, on average, 30 CME credits a year in each of the 3-year blocks (ie, 90 units in each block).2


Self-assessment

SA is a specific form of CME that is designed to provide comprehensive test-based feedback on knowledge acquired, to enhance the learning process.4 SA CME feedback must include:
   • the correct answer to each test question
   • recommended literature resources for each question
   • performance compared to peers on each question.

Given the structured nature of SA activi­ties, beginning January 1, 2014, one must use only ABPN-approved SA products (see Related Resources for a list of APBN-approved SA products).5

Table 1 and Table 2 outline SA require­ments for, respectively, physicians who certified or recertified from 2005 through 2011, and those who certified or recertified in 2012 (and later). The SA requirement increases after 2011 to 24 credits in each 3-year block (8 credits a year, on average).2 Multiple SA activities can be used to fulfill the credit requirement of each 3-year block.




Note: Credits accrued by performing SA activities count toward the CME credit total.


Improvement in medical practice, or PIP

Physicians who are active clinically must complete PIP modules. Each module comprises peer or patient feedback plus a clinical aspect. The May 2014 MOC revi­sion simplified the feedback process to mandate peer or patient feedback—but not both, as required previously.2 For the feedback PIP module, the physician selects 5 peers or patients to complete review forms, examines the results, and creates a plan of improvement. An exception to this “rule of 5” applies to diplomates who have a supervisor capable of evaluating all gen­eral competencies, defined below.

Related Resources
provides a link to ABPN-created forms.

Within 24 months, but not sooner than 1 month, 5 peers or patients (or 1 appli­cable supervisor) are selected to complete review forms; changes in practice are noted. The same peers or patients might be selected for a second review. As noted in Table 1 and Table 2, the number of PIP modules is fewer for physicians who certi­fied or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2

There are 6 ABPN-approved feedback module options, of which the diplomate must choose 1 in any given block2:
   • 5 patient surveys
   • 5 peer evaluations of general competenciesa
   • 5 resident evaluations of general competenciesa  
   • 360° evaluation of general competencies,a with 5 respondents
   • institutional peer review of general competencies,a with 5 respondents
   • 1 supervisor evaluation of general competencies.a

 

 

aGeneral competencies include patient care; practice-based learning and improvement; professionalism; medical knowledge; interpersonal and communication skills; and system-based practices.

Although many institutions have a quality improvement (QI) program, that program must be approved by the Multi-Specialty MOC Portfolio Approval Program sponsored by ABMS for a clinician to receive credit for 1 PIP clinical module. If the approved QI program includes patient or peer feedback (eg, a survey), the diplo­ mate can receive credit for 1 PIP feedback module.2

For the clinical PIP module, the physician selects 5 charts for review and examines them based on criteria found in an ABPN-approved (starting in 2014) PIP product. (Related Resources provides a link to this list.) After reviewing the initial 5 charts, a plan for improvement is created. Within 24 months, but no sooner than 1 month, 5 charts are again selected and reviewed, and changes in practice are noted. The same charts can be selected for the second review.

As noted in Table 1 and Table 2, the number of PIP modules is fewer for those who initially certified or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2


The C-MOC process

Physicians who certified or recertified in 2012, or who will certify or recertify after that year, are enrolled automatically in C-MOC.6,7 The purpose of C-MOC is to keep diplomates on track to fulfill the higher level of SA requirements that began with this group; this is done by mandating use of the ABPN Physician Folios system. As shown in Table 2, there is no longer a 10-year cycle; instead, there are continuous 3-year stages, within which each diplomate must accrue 90 CME cred­its (on average, 30 credits a year), 24 SA credits (on average, 8 a year), 1 PIP clinical module, and 1 PIP feedback module.6,7

The first 3-year block of C-MOC require­ments will be waived for physicians who complete Accreditation Council on Graduate Medical Education–accredited or ABPN-approved subspecialty training in 2012 or later—if they pass the corre­sponding ABPN subspecialty examination during the first 3-year block of enrollment in C-MOC.2 For diplomates enrolled in C-MOC, failure to track progress of each 3-year block, via the ABPN Physician Folios system, has significant consequences: Those who do not complete the first stage of the program by the end of 3 years will be listed on the ABPN Web site as “certified— not meeting MOC requirements.” Those who do not complete 2 stages by the end of 6 years will be listed as “not certified.”2

Cognitive exam still in place. The only remnant of the old 10-year cycle is the requirement to pass the cognitive examina­tion every 10 years, although the exam can be taken earlier if the diplomate wishes. If all requirements are met and one does not sit for, or fails, the exam, the ABPN Web site will report the diplomate as “not meet­ing MOC requirements.” One can retake the exam within 1 year of the failed or missed exam, but a subsequent failure or missed exam will result in being listed as “not certified.”2

Fee structure. Instead of a single fee paid at the time of the exam(s), physicians in the C-MOC program pay an annual fee that covers participation in ABPN Physician Folios and 1 exam in a 10-year period. Fewer than 10 years of participation, or applying for a combined examination (for diplomates who hold multiple certifica­tions), requires an additional fee.7 


Bottom Line

Maintenance of certification (MOC) is manageable, although it requires you to be familiar with its various elements. Those elements include continuing medical education (CME requirements); the additional self-assessment component of CME; performance-in-practice modules; and continuous maintenance of certification. The MOC program booklet of the American Board of Psychiatry and Neurology provides all necessary details.

Disclosure
Dr. Meyer reports no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Faulkner LR, Tivnan PW, Winstead DK, et al. The ABPN Maintenance of Certification Program for psychiatrists: past history, current status, and future directions. Acad Psychiatry. 2008;32(3):241-248.
2. Maintenance of Certification Program. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/ downloads/moc/moc_web_doc.pdf. Published May 2014. Accessed August 25, 2014.
3. Faulkner LR, Vondrak PA. Frequently asked questions about maintenance of certification (MOC). J Clin Psychiatry. 2010;71(5):632-633.
4. Ebert MH, Faulkner L, Stubbe DE, et al. Maintenance of certification in psychiatry. J Clin Psychiatry. 2009;70(10):e39.
5. Approved MOC Products. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/moc_products. asp. Accessed August 25, 2014.
6. Continuous MOC (C-MOC). American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/ContinuousCertificationApproach_0311.pdf. Accessed August 25, 2014.
7. C-MOC Program Overview. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/moc-handouts-CMOC-051314.pdf. Published May 13, 2014. Accessed August 25, 2014.

Article PDF
Author and Disclosure Information

Jonathan M. Meyer, MD
Psychopharmacology Consultant
California Department of State Hospitals
Medical Director
Mental Health Intensive Case Management
VA San Diego Healthcare System
San Diego, California
Assistant Clinical Professor of Psychiatry
University of California, San Diego
San Diego, California
Associate Clinical Professor of Psychiatry
Loma Linda University
Loma Linda, California

Issue
Current Psychiatry - 14(1)
Publications
Topics
Page Number
37-41
Legacy Keywords
MOC, maintenance of certification, MOC credit requirements, American Board of Psychiatry and Neurology (ABPN)
Sections
Author and Disclosure Information

Jonathan M. Meyer, MD
Psychopharmacology Consultant
California Department of State Hospitals
Medical Director
Mental Health Intensive Case Management
VA San Diego Healthcare System
San Diego, California
Assistant Clinical Professor of Psychiatry
University of California, San Diego
San Diego, California
Associate Clinical Professor of Psychiatry
Loma Linda University
Loma Linda, California

Author and Disclosure Information

Jonathan M. Meyer, MD
Psychopharmacology Consultant
California Department of State Hospitals
Medical Director
Mental Health Intensive Case Management
VA San Diego Healthcare System
San Diego, California
Assistant Clinical Professor of Psychiatry
University of California, San Diego
San Diego, California
Associate Clinical Professor of Psychiatry
Loma Linda University
Loma Linda, California

Article PDF
Article PDF

To recap what I discussed in Part 1 of this article (December 2014): As part of a trend across all medical specialty boards, the American Board of Psychiatry and Neurology (ABPN) instituted a recertification pro­cess for all new general psychiatry certifications, starting October 1, 1994.1 In 2000, the specialties that comprise the American Board of Medical Specialties (ABMS) agreed to develop a comprehensive maintenance of certification (MOC) process to demonstrate ongoing learning and com­petency beyond what can be captured by a recertification examination. All ABMS member boards now use a 4-part process for recertification.

A great deal of professional and personal importance has been attached to maintaining one’s general and sub­specialty certifications. To that end, the 2 parts of this article highlight current ABPN MOC requirements and provide resources for understanding, tracking, and completing the self-assessment (SA) and performance-in-practice (PIP) components.

In this installment, I examine 3 components of MOC:
   • continuing medical education (CME), including SA requirements
   • improvement in medical practice (PIP)
   • continuous maintenance of certification (C-MOC)

In addition to this review, all physicians who are subject to MOC should download and read the 20-page revised MOC Program booklet v. 2.1 (May 2014).2

Continuing medical education
The CME requirement is clear: All diplo­mate physicians must accrue, on average, 30 Category-1 CME credits a year; the CME must be relevant to the specialty or subspecialty in which the diplomate prac­tices.3 For physicians who hold >1 ABPN certificates, the total CME requirement is the same; CME credits can be applied across each specialty and subspecialty.

The May 2014 MOC revision states that, for physicians who certified or recertified between 2005 and 2011 and who applied for the 2015 examination in 2014, the required CME credit total is 270.2 For all subsequent years of certification or recertification, including 2012, diplomates are enrolled in C-MOC, which is described below.2

To even out the accrual of CME credits across the prior 10 years, ABPN mandates that, for diplomates who certified or recer­tified between 2005 and 2011, one hundred fifty of the CME credits be accrued in the 5 years before they apply for the examina­tion. Diplomates in C-MOC should accrue, on average, 30 CME credits a year in each of the 3-year blocks (ie, 90 units in each block).2


Self-assessment

SA is a specific form of CME that is designed to provide comprehensive test-based feedback on knowledge acquired, to enhance the learning process.4 SA CME feedback must include:
   • the correct answer to each test question
   • recommended literature resources for each question
   • performance compared to peers on each question.

Given the structured nature of SA activi­ties, beginning January 1, 2014, one must use only ABPN-approved SA products (see Related Resources for a list of APBN-approved SA products).5

Table 1 and Table 2 outline SA require­ments for, respectively, physicians who certified or recertified from 2005 through 2011, and those who certified or recertified in 2012 (and later). The SA requirement increases after 2011 to 24 credits in each 3-year block (8 credits a year, on average).2 Multiple SA activities can be used to fulfill the credit requirement of each 3-year block.




Note: Credits accrued by performing SA activities count toward the CME credit total.


Improvement in medical practice, or PIP

Physicians who are active clinically must complete PIP modules. Each module comprises peer or patient feedback plus a clinical aspect. The May 2014 MOC revi­sion simplified the feedback process to mandate peer or patient feedback—but not both, as required previously.2 For the feedback PIP module, the physician selects 5 peers or patients to complete review forms, examines the results, and creates a plan of improvement. An exception to this “rule of 5” applies to diplomates who have a supervisor capable of evaluating all gen­eral competencies, defined below.

Related Resources
provides a link to ABPN-created forms.

Within 24 months, but not sooner than 1 month, 5 peers or patients (or 1 appli­cable supervisor) are selected to complete review forms; changes in practice are noted. The same peers or patients might be selected for a second review. As noted in Table 1 and Table 2, the number of PIP modules is fewer for physicians who certi­fied or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2

There are 6 ABPN-approved feedback module options, of which the diplomate must choose 1 in any given block2:
   • 5 patient surveys
   • 5 peer evaluations of general competenciesa
   • 5 resident evaluations of general competenciesa  
   • 360° evaluation of general competencies,a with 5 respondents
   • institutional peer review of general competencies,a with 5 respondents
   • 1 supervisor evaluation of general competencies.a

 

 

aGeneral competencies include patient care; practice-based learning and improvement; professionalism; medical knowledge; interpersonal and communication skills; and system-based practices.

Although many institutions have a quality improvement (QI) program, that program must be approved by the Multi-Specialty MOC Portfolio Approval Program sponsored by ABMS for a clinician to receive credit for 1 PIP clinical module. If the approved QI program includes patient or peer feedback (eg, a survey), the diplo­ mate can receive credit for 1 PIP feedback module.2

For the clinical PIP module, the physician selects 5 charts for review and examines them based on criteria found in an ABPN-approved (starting in 2014) PIP product. (Related Resources provides a link to this list.) After reviewing the initial 5 charts, a plan for improvement is created. Within 24 months, but no sooner than 1 month, 5 charts are again selected and reviewed, and changes in practice are noted. The same charts can be selected for the second review.

As noted in Table 1 and Table 2, the number of PIP modules is fewer for those who initially certified or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2


The C-MOC process

Physicians who certified or recertified in 2012, or who will certify or recertify after that year, are enrolled automatically in C-MOC.6,7 The purpose of C-MOC is to keep diplomates on track to fulfill the higher level of SA requirements that began with this group; this is done by mandating use of the ABPN Physician Folios system. As shown in Table 2, there is no longer a 10-year cycle; instead, there are continuous 3-year stages, within which each diplomate must accrue 90 CME cred­its (on average, 30 credits a year), 24 SA credits (on average, 8 a year), 1 PIP clinical module, and 1 PIP feedback module.6,7

The first 3-year block of C-MOC require­ments will be waived for physicians who complete Accreditation Council on Graduate Medical Education–accredited or ABPN-approved subspecialty training in 2012 or later—if they pass the corre­sponding ABPN subspecialty examination during the first 3-year block of enrollment in C-MOC.2 For diplomates enrolled in C-MOC, failure to track progress of each 3-year block, via the ABPN Physician Folios system, has significant consequences: Those who do not complete the first stage of the program by the end of 3 years will be listed on the ABPN Web site as “certified— not meeting MOC requirements.” Those who do not complete 2 stages by the end of 6 years will be listed as “not certified.”2

Cognitive exam still in place. The only remnant of the old 10-year cycle is the requirement to pass the cognitive examina­tion every 10 years, although the exam can be taken earlier if the diplomate wishes. If all requirements are met and one does not sit for, or fails, the exam, the ABPN Web site will report the diplomate as “not meet­ing MOC requirements.” One can retake the exam within 1 year of the failed or missed exam, but a subsequent failure or missed exam will result in being listed as “not certified.”2

Fee structure. Instead of a single fee paid at the time of the exam(s), physicians in the C-MOC program pay an annual fee that covers participation in ABPN Physician Folios and 1 exam in a 10-year period. Fewer than 10 years of participation, or applying for a combined examination (for diplomates who hold multiple certifica­tions), requires an additional fee.7 


Bottom Line

Maintenance of certification (MOC) is manageable, although it requires you to be familiar with its various elements. Those elements include continuing medical education (CME requirements); the additional self-assessment component of CME; performance-in-practice modules; and continuous maintenance of certification. The MOC program booklet of the American Board of Psychiatry and Neurology provides all necessary details.

Disclosure
Dr. Meyer reports no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

To recap what I discussed in Part 1 of this article (December 2014): As part of a trend across all medical specialty boards, the American Board of Psychiatry and Neurology (ABPN) instituted a recertification pro­cess for all new general psychiatry certifications, starting October 1, 1994.1 In 2000, the specialties that comprise the American Board of Medical Specialties (ABMS) agreed to develop a comprehensive maintenance of certification (MOC) process to demonstrate ongoing learning and com­petency beyond what can be captured by a recertification examination. All ABMS member boards now use a 4-part process for recertification.

A great deal of professional and personal importance has been attached to maintaining one’s general and sub­specialty certifications. To that end, the 2 parts of this article highlight current ABPN MOC requirements and provide resources for understanding, tracking, and completing the self-assessment (SA) and performance-in-practice (PIP) components.

In this installment, I examine 3 components of MOC:
   • continuing medical education (CME), including SA requirements
   • improvement in medical practice (PIP)
   • continuous maintenance of certification (C-MOC)

In addition to this review, all physicians who are subject to MOC should download and read the 20-page revised MOC Program booklet v. 2.1 (May 2014).2

Continuing medical education
The CME requirement is clear: All diplo­mate physicians must accrue, on average, 30 Category-1 CME credits a year; the CME must be relevant to the specialty or subspecialty in which the diplomate prac­tices.3 For physicians who hold >1 ABPN certificates, the total CME requirement is the same; CME credits can be applied across each specialty and subspecialty.

The May 2014 MOC revision states that, for physicians who certified or recertified between 2005 and 2011 and who applied for the 2015 examination in 2014, the required CME credit total is 270.2 For all subsequent years of certification or recertification, including 2012, diplomates are enrolled in C-MOC, which is described below.2

To even out the accrual of CME credits across the prior 10 years, ABPN mandates that, for diplomates who certified or recer­tified between 2005 and 2011, one hundred fifty of the CME credits be accrued in the 5 years before they apply for the examina­tion. Diplomates in C-MOC should accrue, on average, 30 CME credits a year in each of the 3-year blocks (ie, 90 units in each block).2


Self-assessment

SA is a specific form of CME that is designed to provide comprehensive test-based feedback on knowledge acquired, to enhance the learning process.4 SA CME feedback must include:
   • the correct answer to each test question
   • recommended literature resources for each question
   • performance compared to peers on each question.

Given the structured nature of SA activi­ties, beginning January 1, 2014, one must use only ABPN-approved SA products (see Related Resources for a list of APBN-approved SA products).5

Table 1 and Table 2 outline SA require­ments for, respectively, physicians who certified or recertified from 2005 through 2011, and those who certified or recertified in 2012 (and later). The SA requirement increases after 2011 to 24 credits in each 3-year block (8 credits a year, on average).2 Multiple SA activities can be used to fulfill the credit requirement of each 3-year block.




Note: Credits accrued by performing SA activities count toward the CME credit total.


Improvement in medical practice, or PIP

Physicians who are active clinically must complete PIP modules. Each module comprises peer or patient feedback plus a clinical aspect. The May 2014 MOC revi­sion simplified the feedback process to mandate peer or patient feedback—but not both, as required previously.2 For the feedback PIP module, the physician selects 5 peers or patients to complete review forms, examines the results, and creates a plan of improvement. An exception to this “rule of 5” applies to diplomates who have a supervisor capable of evaluating all gen­eral competencies, defined below.

Related Resources
provides a link to ABPN-created forms.

Within 24 months, but not sooner than 1 month, 5 peers or patients (or 1 appli­cable supervisor) are selected to complete review forms; changes in practice are noted. The same peers or patients might be selected for a second review. As noted in Table 1 and Table 2, the number of PIP modules is fewer for physicians who certi­fied or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2

There are 6 ABPN-approved feedback module options, of which the diplomate must choose 1 in any given block2:
   • 5 patient surveys
   • 5 peer evaluations of general competenciesa
   • 5 resident evaluations of general competenciesa  
   • 360° evaluation of general competencies,a with 5 respondents
   • institutional peer review of general competencies,a with 5 respondents
   • 1 supervisor evaluation of general competencies.a

 

 

aGeneral competencies include patient care; practice-based learning and improvement; professionalism; medical knowledge; interpersonal and communication skills; and system-based practices.

Although many institutions have a quality improvement (QI) program, that program must be approved by the Multi-Specialty MOC Portfolio Approval Program sponsored by ABMS for a clinician to receive credit for 1 PIP clinical module. If the approved QI program includes patient or peer feedback (eg, a survey), the diplo­ mate can receive credit for 1 PIP feedback module.2

For the clinical PIP module, the physician selects 5 charts for review and examines them based on criteria found in an ABPN-approved (starting in 2014) PIP product. (Related Resources provides a link to this list.) After reviewing the initial 5 charts, a plan for improvement is created. Within 24 months, but no sooner than 1 month, 5 charts are again selected and reviewed, and changes in practice are noted. The same charts can be selected for the second review.

As noted in Table 1 and Table 2, the number of PIP modules is fewer for those who initially certified or recertified between 2005 and 2011; from 2012 onward, 1 PIP clinical module is required in each 3-year block.2


The C-MOC process

Physicians who certified or recertified in 2012, or who will certify or recertify after that year, are enrolled automatically in C-MOC.6,7 The purpose of C-MOC is to keep diplomates on track to fulfill the higher level of SA requirements that began with this group; this is done by mandating use of the ABPN Physician Folios system. As shown in Table 2, there is no longer a 10-year cycle; instead, there are continuous 3-year stages, within which each diplomate must accrue 90 CME cred­its (on average, 30 credits a year), 24 SA credits (on average, 8 a year), 1 PIP clinical module, and 1 PIP feedback module.6,7

The first 3-year block of C-MOC require­ments will be waived for physicians who complete Accreditation Council on Graduate Medical Education–accredited or ABPN-approved subspecialty training in 2012 or later—if they pass the corre­sponding ABPN subspecialty examination during the first 3-year block of enrollment in C-MOC.2 For diplomates enrolled in C-MOC, failure to track progress of each 3-year block, via the ABPN Physician Folios system, has significant consequences: Those who do not complete the first stage of the program by the end of 3 years will be listed on the ABPN Web site as “certified— not meeting MOC requirements.” Those who do not complete 2 stages by the end of 6 years will be listed as “not certified.”2

Cognitive exam still in place. The only remnant of the old 10-year cycle is the requirement to pass the cognitive examina­tion every 10 years, although the exam can be taken earlier if the diplomate wishes. If all requirements are met and one does not sit for, or fails, the exam, the ABPN Web site will report the diplomate as “not meet­ing MOC requirements.” One can retake the exam within 1 year of the failed or missed exam, but a subsequent failure or missed exam will result in being listed as “not certified.”2

Fee structure. Instead of a single fee paid at the time of the exam(s), physicians in the C-MOC program pay an annual fee that covers participation in ABPN Physician Folios and 1 exam in a 10-year period. Fewer than 10 years of participation, or applying for a combined examination (for diplomates who hold multiple certifica­tions), requires an additional fee.7 


Bottom Line

Maintenance of certification (MOC) is manageable, although it requires you to be familiar with its various elements. Those elements include continuing medical education (CME requirements); the additional self-assessment component of CME; performance-in-practice modules; and continuous maintenance of certification. The MOC program booklet of the American Board of Psychiatry and Neurology provides all necessary details.

Disclosure
Dr. Meyer reports no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

References


1. Faulkner LR, Tivnan PW, Winstead DK, et al. The ABPN Maintenance of Certification Program for psychiatrists: past history, current status, and future directions. Acad Psychiatry. 2008;32(3):241-248.
2. Maintenance of Certification Program. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/ downloads/moc/moc_web_doc.pdf. Published May 2014. Accessed August 25, 2014.
3. Faulkner LR, Vondrak PA. Frequently asked questions about maintenance of certification (MOC). J Clin Psychiatry. 2010;71(5):632-633.
4. Ebert MH, Faulkner L, Stubbe DE, et al. Maintenance of certification in psychiatry. J Clin Psychiatry. 2009;70(10):e39.
5. Approved MOC Products. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/moc_products. asp. Accessed August 25, 2014.
6. Continuous MOC (C-MOC). American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/ContinuousCertificationApproach_0311.pdf. Accessed August 25, 2014.
7. C-MOC Program Overview. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/moc-handouts-CMOC-051314.pdf. Published May 13, 2014. Accessed August 25, 2014.

References


1. Faulkner LR, Tivnan PW, Winstead DK, et al. The ABPN Maintenance of Certification Program for psychiatrists: past history, current status, and future directions. Acad Psychiatry. 2008;32(3):241-248.
2. Maintenance of Certification Program. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/ downloads/moc/moc_web_doc.pdf. Published May 2014. Accessed August 25, 2014.
3. Faulkner LR, Vondrak PA. Frequently asked questions about maintenance of certification (MOC). J Clin Psychiatry. 2010;71(5):632-633.
4. Ebert MH, Faulkner L, Stubbe DE, et al. Maintenance of certification in psychiatry. J Clin Psychiatry. 2009;70(10):e39.
5. Approved MOC Products. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/moc_products. asp. Accessed August 25, 2014.
6. Continuous MOC (C-MOC). American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/ContinuousCertificationApproach_0311.pdf. Accessed August 25, 2014.
7. C-MOC Program Overview. American Board of Psychiatry and Neurology Inc. http://www.abpn.com/downloads/ moc/moc-handouts-CMOC-051314.pdf. Published May 13, 2014. Accessed August 25, 2014.

Issue
Current Psychiatry - 14(1)
Issue
Current Psychiatry - 14(1)
Page Number
37-41
Page Number
37-41
Publications
Publications
Topics
Article Type
Display Headline
Second of 2 parts: The mysteries of psychiatry maintenance of certification, further unraveled
Display Headline
Second of 2 parts: The mysteries of psychiatry maintenance of certification, further unraveled
Legacy Keywords
MOC, maintenance of certification, MOC credit requirements, American Board of Psychiatry and Neurology (ABPN)
Legacy Keywords
MOC, maintenance of certification, MOC credit requirements, American Board of Psychiatry and Neurology (ABPN)
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media